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SUMMARY 
 
Chronotherapy is a form of therapy where treatment is administered according to a 
schedule that corresponds to an individual’s biological clock. Research demonstrates 
that the body’s natural processes follow a 24-hour pattern, or circadian rhythm. In 
addition, symptoms of disease fluctuate according to this 24-hour pattern. These 
diseases, termed chronotherapeutic disorders may include amongst other disorders, 
hypertension, cardiovascular disease and asthma. Common therapy for these 
disorders involves the use of controlled zero-order release formulations. Here, the 
same quantity of drug is released over a period of time. Although beneficial, these 
formulations are not ideal in the treatment of chronotherapeutic disorders. Treatment of 
these disorders aims to release drug at specific periods, only when it is required, such 
that therapy coincides with the body’s natural rhythm. Ideally, drug should be released 
in pulses with two or more pulses released from the dosage form. In this manner, the 
patient is exposed to drug only when required, reducing the number of dosages, 
reducing side-effects and ultimately increasing patient compliance. Therefore, the aim 
of this research was to develop a Multi-Layered Multi-Disk Tablet (MLMDT) that 
incorporates two drug-loaded disks enveloped by three polymeric layers. The proposed 
system, to be used in the treatment of chronotherapeutic disorders, is designed to 
provide a lag phase and then two pulses of drug release separated by a ‖switch-off‖ 
phase. During the ―switch-off‖ phase no drug is released from the system. 
 
Initially, preliminary screening studies were performed on various polymeric materials 
to assess their effectiveness to generate the desired drug release profile. Of the 
numerous polymer combination and ratios, only a few were relevant and were 
subsequently tested further. From the preliminary studies it was ascertained that the 
composition of disk 2 was critical in generating the ―switch-off‖ phase separating the 
two pulses. Artificial Neural Networks (ANN); a computational technique that simulates 
the thinking process of the human brain was employed for optimization. Results from 
this technique outlined the polymer combination suitable for the optimized MLMDT. 
The optimized formulations were subjected to friability, hardness and uniformity of 
mass analysis as well as swelling, erosion and magnetic resonance imaging 
techniques to observe and confirm the performance of the MLMDT during dissolution. 
In addition, textural analysis, computational modeling and temperature modulated 
differential scanning calorimetry techniques were used to elucidate any 
incompatibilities or complexes formed. In vitro drug release analysis revealed that the 
MLMDT generated a lag phase followed by two pulses of drug release over the 24 
hour period. The two pulses were separated by a ―switch-off‖ phase. 
 
To confirm data obtained during preclinical in vitro testing, animal studies were 
undertaken using the Large White Pig model. Pigs were dosed with conventional 
products and the optimized MLMDT. Blood samples collected over a 24 hour period 
were analyzed using Ultra Performance Liquid Chromatography to determine the drug 
concentration in blood. Drug concentration analysis from conventional products 
revealed increasing plasma concentrations up to 2 hours followed by a steady decline 
in concentration while the developed MLMDT displayed two pulse drug release 
separated by a ―switch-off‖ phase. 
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CHAPTER ONE 
INTRODUCTION AND MOTIVATION FOR THIS STUDY 
 
 
1.1 Background 
 
Drug may be administered into the body via various routes. These include oral, 
parenteral, buccal, nasal, rectal, pulmonary, transdermal and ocular routes of 
administration. Of these, the oral drug route is the most common and allows for non-
invasive delivery of drug. Oral formulations are easy to manufacture, convenient and 
affordable resulting in an increase in patient compliance (Bredenberg et al., 2003). To 
further facilitate patient compliance controlled release oral formulations are preferred. 
These systems allow for constant or variable drug release. Constant controlled release 
preparations that provide zero-order release are able to maintain a desired drug 
concentration over a prolonged period of time. In recent years, extensive emphasis has 
been placed on constant drug release (Löbenberg et al., 2005). With these systems 
drug release is maintained within a therapeutic window over a prolonged period, 
thereby reducing peak-to-trough fluctuations and ultimately decreasing side-effects and 
the dosage frequency (Figure 1.1). 
 
 
Figure 1.1: Difference in peak plasma concentrations between a conventional release 
formulation and a controlled release formulation (Adapted: Gothoskar et al., 2004). 
 
2 
 
Although these devices have proven to be extremely valuable, there are certain 
diseases when constant prolonged release is not desirable. These diseases are 
termed chronotherapeutic disorders and would benefit from chronotherapy, which 
involves timing drug application to achieve optimal therapeutic success. It is known 
that humans follow a 24-hour cycle known as circadian rhythms, which are controlled 
by a biological clock and work on a daily time scale. Using the concept of circadian 
rhythms, it is possible to treat chronotherapeutic disorders via specialized drug delivery 
systems (Hassan and Haefeli, 2010).  
 
Chronotherapeutics is a branch of therapy that involves synchronizing drug application 
in a manner that matches circadian rhythms in order to achieve optimal therapeutic 
success (Landau, 1991). A major objective of chronotherapy is to deliver drug in higher 
concentrations during the times of greatest need. Conventional zero-order controlled 
release drug delivery systems used in the treatment of chronotherapeutic conditions 
are not designed to complement the circadian rhythm. In order to achieve optimal 
success, drug release ought to match the body’s circadian rhythm and should occur 
after predetermined time delays such that drug release within a 24-hour period is in 
synchrony with the biological determinants of the disease (Pawar and Awasthi, 2010). 
Therefore, to meet these requirements pulsatile drug release is beneficial so that drug 
may be released after a lag-phase at predetermined time intervals (Kalantzi et al., 
2009; Kadam and Gattani, 2010; Kumar et al., 2010). Pulsatile drug delivery offers 
advantages such as, extended day-time or night-time activity, reduced side-effects, 
reduced dosing frequency and dose size, improved patient compliance and lower 
treatment costs. Therefore, this study proposes to design a multi-layered multi-disk 
tablet (MLMDT) for use in chronotherapeutic disorders. The MLMDT is intended to 
produce a lag-phase and two pulses of drug release which are separated by a ―switch-
off‖ phase to coincide with the body’s natural circadian rhythm. During this ―switch-off‖ 
phase drug no drug should be released. 
 
1.2 Rationale and Motivation for the Study 
 
Patient non-compliance is seen as a major drawback in the treatment of disease. A few 
causes of patient non-compliance include side-effects, tolerance and the cost of 
medication. In addition, the frequency of dosing plays a role as patients forget to take 
medication. The proposed MLMDT aims to address these issues. The timing of drug 
administration such that drug is only released when required in a 24-hour period, 
implies that the patient is not continually exposed to drug thereby reducing side-effects. 
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Furthermore as the body is not constantly exposed to the drug, tolerance to a drug can 
be avoided. The aim of the MLMDT is to produce a lag phase followed by two pulses of 
drug release equivalent to administering two doses. This, together with the use of low 
cost materials reduces the medication costs. Also the dosing frequency is reduced to 
once a day increasing patient compliance. 
 
The proposed chronotherapeutic drug delivery system should aim to deliver drug after 
a predetermined time interval, deliver drug when it is most needed in a 24-hour period 
and reduce drug release when not needed (e.g. when the patient is asleep). A 
schematic depicting the desired release profile is represented in Figure 1.2. 
 
Figure 1.2: Schematic depicting the desired release profile. 
 
To achieve this desired release profile requires a complex interplay between a variety 
of polymers. As two pulses of release are required, the first pulse is required to release 
after a lag phase of approximately 2 hours whereas the second pulse is required to 
release after approximately 12-15 hours (Figure 1.2). Drug release in this manner may 
provide therapeutic blood levels similar to those produced by two smaller doses 
reducing the number of doses required, thereby reducing side-effects improving patient 
compliance and reducing cost of treatment. Furthermore, this release pattern ensures 
that drug is delivered during the period when it is most needed. 
 
The proposed MLMDT comprises two drug-loaded disks, enveloped by three polymeric 
drug-free barrier layers (Figure 1.3). The barrier layers control the rate at which drug is 
Second pulse of 
drug release 
―Switch-off‖ 
phase 
First 
pulse of 
drug 
release 
Lag 
phase 
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released from the disks. It is envisaged that the MLMDT will be dosed every evening 
(approximately 6pm) and will release drug after a lag phase. Thereafter, drug release 
will cease as the barrier layers protect the second disk from release. The second pulse 
will be released at approximately 4am and drug release will continue till the next dose 
thus providing pulsatile drug release that takes circadian variation into consideration 
and minimizes toxic effects. 
 
The design may apply to any drug that is used to treat chronotherapeutic conditions, as 
well as allowing for more than one drug to be combined in a single drug delivery 
system. In this study theophylline (THP) and diltiazem HCL (DTZ) were employed as 
model drugs.  
 
 
 
Figure 1.3: Schematic of the MLMDT comprising of two drug disks enveloped by a 
polymeric matrix.  
 
Even though THP preparations have been replaced with newer drugs in the treatment 
of asthma they may still be useful in the treatment of nocturnal asthma and COPD 
(Kraft and Martin, 1995; Caramori and Adcock, 2003; Gothaskar et al., 2004; 
Mastiholimath et al., 2007; Kadam and Gattani, 2010). THP also serves as a model 
drug where circadian variability and chronobiology may affect the release of a drug 
(Pollock and Olanoff, 1990). A study conducted by Jonkman et al,. in 1984 
demonstrated that plasma concentration after 12 hours of a morning dose of THP were 
lower than that of an identical preparation dosed at night. This phenomonan was also 
observed when intravenous THP was used. It was concluded that a circadian pattern 
was responsible for lengthening the half-life during the evening hours (Jonkman et al,. 
1984).  
Layer One: Polymeric 
matrix 
Disk 1: Drug formulated 
in a matrix 
Layer 2: Polymeric 
matrix 
Disk 2: Drug formulated 
in a matrix 
 1: Polymeric 
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Chronotherapeutic dosing of THP once daily in the evening between 6 p.m. and 7 p.m., 
attenuates nocturnal symptoms and early morning bronchoconstriction without the 
deterioration of asthma control at other times of the day. This regimen has been found 
to be clinically superior to conventional twice-daily dosing (Welsh et al., 1986; 
Grossman, 1988; Martin et al., 1989). A single-blind, randomized, crossover study 
compared equivalent doses of once-daily THP tablets with twice-daily THP tablets in 
patients who repeatedly experienced 20% or greater declines in PEFR during the 
night. The overnight decrease in FEV 1 was 12% after the once-daily preparation 
compared with 34% after the twice-daily preparation (Martin et al., 1989). In addition, 
evidence suggests that THP dosed at night may have a positive cumulative impact on 
lung function. A trial compared a once-daily, controlled-release THP preparation given 
in the morning or evening with twice-daily THP therapy (Grossman, 1988). The 
outcome of this trial proved the once-daily evening THP dosing produced significantly 
higher morning PEFRs and fewer night time awakenings compared with the twice-daily 
THP regimen. Thus, a once-daily evening dosage regimen is effective in controlling 
nightly asthma symptoms without compromising daytime control of asthma. 
 
Chronotherapy with THP has proven effective in COPD patients with nocturnal 
worsening of lung function. Improved and more stable spirometric performances have 
been documented in patients treated with once-daily THP chronotherapy. A study was 
conducted on patients who received a placebo, once daily dose of controlled release 
THP at 10 p.m. or a twice daily dosage of extended release THP at 8 a.m. and 8 p. m. 
Results found that patients receiving the once daily dosage demonstrated significant 
improvement as compared to the other two groups (Rivington et al., 1988), indicating 
that extended release THP appears to be efficacious both objectively and subjectively 
in patients with asthma or COPD. 
 
1.3 Aim and Objectives of the Study 
 
The aim of this study was to focus on in vitro and in vivo development and evaluation 
of a novel MLMDT for use in two specific chronotherapeutic disorders, namely asthma 
and hypertension. As previously mentioned, the MLMDT should produce the desired 
release profile which exhibits pulsatile drug delivery after an initial lag phase. 
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In order to accomplish this aim the following specific objectives were outlined:  
 
 Evaluating the physicochemical, physicomechanical and micromeritic 
properties of polymeric materials for potential use in the formulation. 
 Undertaking compatibility studies between the model drugs and the polymers 
to determine if any unfavorable interactions exist between the materials. 
  Assessing the in vitro drug release rates using simulated gastric and intestinal 
media.  
 Undertaking bio-erosion and swelling studies. 
 Performing in-process validation testing by determining the friability, uniformity 
of mass and hardness.  
 Performing in vivo animal studies, to determine the drug release and plasma 
profile. 
 
1.4. Overview of this Dissertation 
 
Chapter One provides an overview into the concept of chronotherapy as well as 
highlighting the importance of this concept in disease. The rationale and motivation of 
the study is explained and the aims and objectives are summarized.  
 
Chapter Two provides an introduction into the concept of chronotherapy and explains 
the role of chronotherapy in disease. Furthermore, current chronopharmaceuticals are 
discussed.  
 
Chapter Three describes preliminary studies which includes the formulation and 
development of the MLMDT as well as in vitro studies and in-process validation. 
 
Chapter Four focuses on optimization of the formulation using Artificial Neural 
Networks. Various experiments on the optimized formulation are also described 
including compatibility studies and analyses of physicochemical and 
physicomechanical properties of the MLMDT. 
 
Chapter Five outlines the in vivo animal studies undertaken in the large white pig 
model. In addition, a method of analyses and plasma-drug profiles are explained. 
 
Chapter Six presents the conclusions and recommendations for future work.  
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CHAPTER TWO 
LITERATURE REVIEW OF CURRENT DRUG DELIVERY TECHNOLOGIES 
EMPLOYED TO TREAT CHRONOTHERAPEUTIC DISORDERS 
 
 
2.1 Introduction 
 
During the 1700s Jean-Jacques d’Ortous de Mairan was the first researcher to take 
note of the 24-hour patterns occurring in the movement of a plant. Since then research 
has been conducted to prove the presence of the 24-hour cycle. The 24-hour cycle that 
takes place in physiological processes of all human beings is termed the circadian 
rhythm. Other biological rhythms include the ultradian (length of hours, minutes or 
seconds), infradian (length of days or months), circatrigantan (the female menstrual 
cycle) and circannual rhythms (seasonal variation) (Gherghel et al., 2004; Haus, 2007).  
 
The term circadian rhythm was first coined by Halberg and Stephens in 1959 and 
literally means ―about-a-day‖ (Eriguchi et al., 2003; Gherghel et al., 2004). It was then 
found that the human biological clock is coordinated by the suprachiasmatic nucleus 
located at the base of the hypothalamus (Lévi, 2001). The suprachiasmatic nucleus is 
a paired nucleus situated above the optic nerve. Light that passes through the retina 
conducts impulses to the retino-hypothalamic tract that in turn regulates nine genes 
(Table 2.1.) that create 24-hour variations in cellular physiological processes (Dunlap, 
1999; Shearman et al., 2000; Gherghel et al., 2004). The suprachiasmatic nucleus 
inherently possesses a pacemaker which produces endogenous electrical activity thus 
allowing variations in the suprachiasmatic nucleus to arise in the absence of external 
stimuli (Gherghel et al., 2004). The biological rhythms generated play a role in 
controlling biological functions that include the autonomic nervous system, endocrine 
system and immune system (Figure 2.1) (Eriguchi et al., 2003).  
 
The circadian clock essentially comprises three components: an input pathway 
(photoreceptors and projections of retinal ganglion cells), circadian pacemakers that 
generate the circadian signal and an output pathway that couples the pacemakers to 
effector systems manifesting into circadian physiology and behavior (Aronson et al., 
1993; Ohdo, 2007; Ohdo, 2010).  
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Table 2.1: Genes associated with the bodies’ circadian rhythm. 
Genes responsible for circadian rhythms 
PER 1 CLOCK 
PER 2 BMAL1 
PER 3 TIM 
CLOCK CRY1 
BMAL1 CRY2 
TIM tau 
 
 
 
 
 
Gene 
Regulation
SCN
Pineal Gland
Melatonin 
Release
Autonomic 
System
Immune Endocrine
System
 
Figure 2.1: Schematic depicting the influence of light on the hypothalamus affecting 
gene regulation, melatonin release and the autonomic, endocrine, and immune 
system. 
 
The circadian clock behaves like a multifunctional timer in order to regulate 
homeostatic systems within the human body (Ohdo, 2007; Ohdo, 2010). The most 
frequently used methods to assess the circadian rhythms in humans are: 
 
 plasma melatonin release 
 core body temperature measurement 
 plasma cortisol level 
 dim light melatonin onset 
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Melatonin production starts rising in the evening and thus is used as an indication of 
the circadian phase (Lewy et al., 1999). Collection of an individual’s core body 
temperature is an easy measurement of circadian rhythm. Body temperature rises 
during the day with the maximum temperature occurring at 5 p.m. This is followed by a 
nocturnal decline is observed with a minimum temperature occurring at 5 a.m. Cortisol 
is released in a rhythmic manner and declines throughout the day. A nocturnal ―quiet 
phase‖ occurs during the evening where low concentrations are released. This is 
followed by a rise occurring in the second half of the night leading towards a morning 
maximum (Hofstra et al., 2008). 
 
Circadian rhythms govern nearly all functions in the body, including sleep and activity, 
hormone levels, appetite and those functions responsible for pharmacokinetic 
parameters (Lemmer, 1991; Lemmer, 1996, Ohdo, 2007). Furthermore, hormones 
such as cortisol, rennin, growth hormone and aldosterone also display daily 
fluctuations (Lemmer, 1996; Ohdo, 2010). The secretion of growth hormone peaks 
during sleep with aldosterone and cortisol levels typically peaking during the morning 
(Elliot, 2001). A list of hormones and biological functions that are known to follow a 
circadian rhythm are highlighted in Table 2.2.  
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Table 2.2.: The effect of circadian rhythmicity on the secretion of hormones and 
biological functions (Lemmer 1990, Lemmer, 1996, Youan 2004). 
Circadian Rhythmicity Hormone/Biological Functions 
Late at night/early in sleep  Gastric Acid Secretion 
 White Blood Cell Count 
 Calcitonin Gene-Related Protein 
 Atrial Natriuretic Peptide 
 
Peaks during sleep  Growth Hormone 
 Thyroid stimulating Hormone 
 Melatonin 
 Prolactin 
 Follicle Stimulating Hormone 
 Adrenocorticotropic Hormone 
 Luteinizing Hormone 
 
Peaks during the morning  Cortisol 
 Renin 
 Angiotensin 
 Vascular Resistance 
 Platelet Aggregation 
 Blood Viscosity 
 
Peaks at noon  Hemoglobin 
 Insulin Release 
 
Peaks in the evening  Triglycerides 
 Urinary Diuresis 
 Cholesterol 
 
A thorough knowledge of the circadian clock helps in understanding the 24-hour 
biological clock as well as the pathophysiology and symptoms of disease. Also the 
pharmacokinetics and pharmacodynamics of various drugs can be further understood. 
Information on the circadian rhythms and their influence on disease states may assist 
formulation scientists in developing innovative approaches for drug delivery and other 
treatment modalities.  
 
2.2 The Role of Circadian Rhythms in Disease 
 
Diseases that follow the daily biological rhythms are known as chronotherapeutic 
disorders. The symptoms of these disorders are exacerbated or more prominent at 
certain times during the day. The biological systems known to follow a circadian rhythm 
are described hereunder.  
 
2.2.1 The cardiovascular system 
Several functions of the cardiovascular system such as the heart rate, stroke volume, 
fibrinolytic activity, platelet aggregability, cardiac output and blood flow follow a 
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circadian rhythm (Kraft and Martin, 1995; Smolensky, 1995; Lemmer, 1996; Takeda 
and Marmora, 2010). Blood pressure and heart rate in both normotensive and 
hypertensive patients are higher during the morning hours (6 a.m. to 12 p.m.) than any 
other time of the day due to a decrease in sympathetic output occurring at night while 
asleep (Prisant, 2001; Smith, 2001; Lemmer, 2006; Hermida et al., 2007; Smolensky 
and Peppas, 2007; Portaluppi and Hermida, 2007; Hermida and Ayala, 2009). Upon 
waking, the systolic blood pressure rises rapidly by 20-25mmHg and diastolic blood 
pressure by 10-15mmHg (Smolensky and Peppas, 2007). Gherghel et al. (2004) 
expressed the extent of the drop in blood pressure during the night in the region of 10-
20%.  
 
It is further described that approximately two thirds of the world’s population present 
with a blood pressure drop of this magnitude during the night and are known as 
dippers. The remaining one third present with a blood pressure drop of <10% and are 
known as non-dippers. These factors, in conjunction with the prolonged exposure to a 
higher blood pressure level seen in non-dippers, contributes to an increase in 
cardiovascular diseases such as myocardial infarctions, angina and strokes during the 
early hours of the morning (Kraft and Martin, 1995; Smolensky and Portaluppi, 1999; 
Smith, 2001; Douglas, 2002; Portaluppi and Hermida, 2007). Douglas, (2007) reported 
that there is a 40% higher risk of a heart attack, a 29% increased risk of cardiac death 
and a 49% increased risk of stroke between 6 a.m. and 12 p.m. in the morning. 
Conversely, vasospasms in Prinzmetal angina and congestive heart failure symptoms 
are common during sleep (Gallerani et al., 1992; Kraft and Martin, 1995; Smolensky 
and Portaluppi, 1999). Furthermore, the diagnosis of hypertension is based on the 
assessment of blood pressure when a patient presents at the doctor during the 
daytime. However, blood pressure fluctuates during the day and a single measurement 
during the day is not representative of the systolic and diastolic blood pressure 
throughout the day. The use of 24-hour blood pressure ambulatory monitoring 
technology is required to establish a correct diagnosis (Smolensky and Peppas, 2007; 
Portaluppi and Smolensky, 2010). 
 
2.2.2 The respiratory system 
Lung function is also affected by circadian rhythms. Lung function in healthy patients 
dips during the early hours of the morning. This change is more pronounced in 
asthmatic patients. The decrease in lung function can vary between 25-50% (Kraft and 
Martin, 1995). Airway resistance in asthmatic patients increases progressively at night 
(Martin and Banks-Schlegel, 1998; Burkioka et al., 2002; Sutherland, 2005; 
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Mastiholimath et al., 2007; Shiohira et al., 2009). At night the lungs are more sensitive 
to bronchoconstrictors such as acetylcholine and histamine (Lemmer, 1996; Gwen, 
2002; Smolensky et al., 2007). A survey conducted by Turner-Warwick (1988) 
demonstrated that of 7600 asthmatic patients interviewed, 74% awoke from sleep with 
asthmatic symptoms. Treatment of asthma involves the inhalation of corticosteroids 
that directly inhibits inflammatory cells. A study conducted on individuals affected with 
asthma ascertained that dosing an inhaled corticosteroid once daily at 3 p.m. was as 
effective as four times daily dosing (Pincus et al., 1995). In another study, dosing with 
inhaled corticosteroids at 8 a.m. and 5:30 p.m. were compared to four times daily 
dosing. The outcome of the study proved that dosing at 5:30 p.m. was as effective as 
dosing four times daily, however dosing at 8 a.m. did not produce results comparable 
to four times daily dosing (Pincus et al., 1997). Optimal dosing of inhaled 
corticosteroids was thus between 3:00-5:30p.m. These observations highlight the 
significance of dosing medication in synchrony with the body’s circadian rhythms.  
 
2.2.3 The skeletal system  
Patients suffering from rheumatoid arthritis are inclined to experience pain symptoms 
during the morning due to an increase in the concentration of interleukin-6 and C-
reactive protein. Patients with rheumatoid arthritis also display circadian rhythms in 
joint pain and finger swelling. These debilitating symptoms are in phase with the 
circadian rhythms of pain (Cutolo, 2003). In contrast, osteoarthritic patients have less 
pain during the morning compared to the rest of the day (Youan, 2004, Sher et al., 
2007). Timing the treatment of arthritis is important as non-steroidal anti-inflammatory 
drugs are also affected by the timed daily scale. Studies have demonstrated that a 
large dose taken twice daily is more effective than four smaller doses, provided that 
one of the doses is taken at night (Kraft and Martin, 1995).  
 
2.2.4 The gastrointestinal system 
Gastric acid secretion follows a circadian rhythm with a rapid surge of gastric acidity for 
at least one hour at midnight resulting in a decrease in the gastric pH level (Fass, 
2004; Castilla-Guerra et al., 2009; Bahammam et al., 2010; Hsieh and Ohman, 2010; 
Kaya et al., 2010; Reddy and O’neill, 2010; Rosenwasser, 2010; Sewlall et al., 2010; 
Diskmeis and Foulkes, 2011; Stalder et al., 2011). This change in pH may result in 
circadian modifications of drug ionization according to its properties (Van Herwaarden 
et al., 1999; Farup et al., 2001). A previous study conducted revealed that gastric 
emptying rates for meals eaten at 8 p.m. was on average 50% slower than the same 
meal eaten at 8 a.m. (Goo et al., 1987). This observation has implications in the 
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pharmacokinetics of orally administered drugs. The drug disintegration, dissolution and 
absorption may also be slower at night. In addition, the increase in acid secretion may 
exacerbate duodenal ulcers in affected patients (Sanders and Moore, 1998; Youan, 
2004) and consequently a once daily dosage in the evening has been advocated 
(Lemmer, 1991; Youan, 2004; Roy and Shahiwala, 2009).  
 
2.2.5 The role of circadian rhythms in glaucoma 
In the United States open angle glaucoma is the second leading cause of blindness 
(Wax et al., 2002). Primary open angle glaucoma is characterized by atrophy of the 
optic nerve, increased intraocular pressure and visual defects (Wax et al., 2002; 
Gherghel, 2004). The main cause of primary open angle glaucoma is an increased 
intraocular pressure due to a reduction in aqueous humor drainage. The secretion of 
aqueous humor follows a circadian rhythm with a greater quantity secreted during the 
day compared to the night as the two hormones known to be responsible for secretion, 
namely cortisone and epinephrine/adrenalin, display concentrations that are lower at 
night than during the day (Jacob et al., 1996).  
 
2.2.6 The role of circadian rhythms in cancer 
The risk of developing cancer as well as its treatment has links with circadian 
rhythmicity. Cell proliferation and metabolism as well as apoptosis and DNA repair are 
under circadian control (Matsuo et al., 2003; Gery et al., 2006). In other studies it has 
been suggested that women who worked night-shifts for long periods of time had a 
higher risk of developing breast, colorectal and endometrial cancer (Keith et al., 2001; 
Schernhammer et al., 2001; Davis et al., 2006; Hansen et al., 2006; Stevens, 2006; 
Viswanathan et al., 2007; Pushkala and Gupta, 2009). Similarly, in men shift-work was 
associated with an increase in the risk of developing prostate cancer (Kubo et al., 
2006; Conlon et al., 2007). In the treatment of cancer to achieve efficacious therapeutic 
outcomes patients often receive treatment where the dosage of drug is near the 
maximum tolerated dose. As a result, there is always the possibility of toxicity to 
normal cells. Due to normal cell physiology following a 24-hour clock, synchronizing 
the dosing schedule of chemotherapeutic agents to match the circadian rhythm of cells 
may result in a reduction in the cytotoxicity of these agents. The extent of toxicity and 
the efficacy of more than thirty different anticancer drugs are influenced by circadian 
dosing time (Mormont and Lévi, 2006; Lévi et al., 2007; Innominato et al., 2010). For 
example, platinum analog complexes such as cisplatin, carboplatin and oxaliplatin are 
best tolerated near the middle of the nocturnal activity span of laboratory mice whereas 
5-flurouracil is best tolerated when it is administered 12 hours earlier than the platinum 
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analogs (Boughattas et al., 1989; Lévi et al., 2007). In another example, a study was 
conducted where the survival rates of patients suffering from acute lymphoblastic 
leukemia were measured. Eighty percent of patients were alive and disease free after 
5 years when dosed with 6-mercaptopurine and methotrexate during the evening and 
only forty percent of patients survived when dosed with the same medication during the 
morning (Lévi et al., 2007). Other anticancer drugs affected by circadian dosing time 
include arabinofuranosylcytosine, 5-fluorouracil deoxyribonucleoside (FUDR), 
doxorubicin, melphalan, cisplatin and oxaliplatin (Lévi, 1997; Focan et al., 2000).  
 
2.2.7 Chronotherapy and sleep 
The circadian system plays a vital role in the sleep-wake cycle. A disruption in the 
circadian timing system or a misalignment between the endogenous circadian timing 
and the external 24 hour social and physical environment can lead to circadian rhythm 
sleep disorders. To correct this disorder, timed exposure to bright light is often 
advocated. Melatonin also proves useful either alone or in combination with bright light 
exposure (Barion and Zee, 2007; Lack et al., 2009; Dodson and Zee, 2010).  
 
2.2.8 Circadian rhythms and normal thyroid function 
The hypothalamic-pituitary-thyroid axis follows a complex time structure. Briefly, the 
hypothalamus releases thryrotropin releasing hormone (TRH) which stimulates the 
pituitary to release thyroid stimulating hormone (TSH). This stimulates the thyroid to 
release thyroid hormones. TSH is released in pulses, however these pulses are not 
equally distributed throughout the day, rather they group together during the evening 
and night peaking between 2 a.m. and 4 a.m. (Brabant et al., 1990; Samuels et al., 
1990). This pulse release may be essential for regular thyroid function and a change in 
this regular nocturnal variation may lead to hypothyroidism (Samuels et al., 1990; 
Innominato et al., 2010). 
 
2.2.9 Cortisol and circadian rhythmicity 
Cortisol release like the release of thyroid hormones is controlled by a complex set of 
influences. The hypothalamus releases corticotrophin-releasing hormone (CRH) which 
acts on the pituitary to release adrenocorticotropic hormone (ACTH) which stimulates 
the adrenal cortex to release cortisol. The SCN inputs information that releases CRH in 
a pulsatile and periodic manner leading to the pulsatile release of ACTH which in turn 
leads to pulsatile release of cortisol. ACTH release peaks during the late night and 
early morning (Hillhouse and Grammatopoulos, 2006). Release then declines during 
the day with smaller pulses during the evening and night (Linkowski et al., 1993). Due 
 
15 
 
to the complex and sensitive nature of this pathway, timing of corticosteroid treatment 
is crucial. When suppression of the secretion of adrenocorticotropic hormone or 
cortisol is required (as in the treatment of congenital adrenal hyperplasia), treatment 
should be administered in the evening which is prior to the circadian rise in ACTH 
release. Administration at this time results in a greater inhibition of the pituitary than 
any other time of the day or night (Moeller, 1985). Alternatively when corticosteroid 
therapy is required for inflammation, medication should be dosed in the morning as it 
leads to minimal adrenal suppression and fewer side-effects. When twice a day dosing 
is required, dosing should take place at 3 p.m. (Beam et al., 1992; Pincus et al., 1995; 
Smolensky et al., 1999, Takahashi et al., 2010). 
 
2.3 Chronotherapy and Drug Delivery 
 
An in-depth knowledge of circadian rhythms is of great importance when administering 
a drug delivery system as numerous drugs display variations in their pharmacokinetics 
and pharmacodynamics. For example, a drug delivery system administered in the 
morning may not have the same pharmacokinetic properties when administered at 
night. This can be attributed to the gastric ion concentration, stomach emptying rate 
and blood flow to the gastrointestinal tract, hepatic bile function, renal blood flow, 
glomerular filtration, and tubular function that follows a 24-hour rhythm (Smolensky and 
Portaluppi, 1999; Smolensky and Peppas, 2007). The pharmacokinetic properties of 
numerous drugs are affected by circadian rhythms, as listed in Table 2.3. 
Chronotherapeutics does not necessarily have to include new drug molecules, but 
instead established drugs may be incorporated into innovative drug delivery systems or 
devices that can be employed to improve their efficacy. This can be accomplished by 
unequal morning and evening dosing of a 12-hour drug delivery system, superior 
timing of a once-a-day formulation or by development of novel drug delivery systems 
that are able to release drug over a 24-hour period in synchrony with the biological 
rhythms (Smolensky and Peppas, 2007).   
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  Table 2.3: Drugs affected by circadian rhythm (Adapted: Lemmer, 1996). 
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2.4 Overview of Chronopharmaceutical Technologies 
 
One of the first commercially available oral products to employ the use of 
chronotherapy is the long-acting bronchodilator Uniphyl® (THP) (Purdue Frederick Co., 
Connecticut, USA). Chronopharmaceutical technologies currently available include: 
CONTIN® (Purdue Pharma, Ontario, Canada), Chronotropic® and Pulsincaps® 
(Catalent Pharma Solutions, New Jersey, USA). CEFORM® (Biovail Corporation, 
Ontario, Canada), TIMERx® (Penwest Pharmaceutical Company, Connecticut, USA), 
OROS® (DURECT Corporation, California, USA), CODAS® (Elan Corporation, Florida, 
USA), Egalet® (Egalet a/s, Copenhagen, Denmark) and Diffucaps® (Eurand 
Pharmaceuticals, Pennsylvania, USA). Table 2.4 defines the significant applications of 
the described technologies in oral drug delivery (Youan, 2004). 
 
Table 2.4: Chronopharmaceuticals currently on the market. 
Trade Name Drug Chronopharmaceutical 
technology 
Rationale for use in 
chronotherapy 
 
Cardizem
®
 LA 
 
Diltiazem HCl 
Verapamil HCl 
 
CEFORM
®
 
 
Hypertensive 
management to reduce 
morning blood 
pressure surge 
 
Covera
®
 HS Verapamil HCl OROS
®
 Hypertensive 
management to reduce 
morning blood 
pressure surge 
 
InnoPran
®
 XL Propranolol Diffucaps
®
 Hypertensive 
management to reduce 
morning blood 
pressure surge 
 
Uniphyl
®
 Theophylline CONTIN
®
 Asthma management 
to reduce early 
morning 
bronchoconstriction 
 
Verelan
® 
PM Verapamil CODAS
®
 Hypertensive 
management to reduce 
morning blood 
pressure surge 
 
2.4.1 CONTIN® 
CONTIN® technology (Purdue Pharma, Ontario, Canada), involves combining a drug 
and hydrophilic polymer followed by selective hydration with a polar solvent and 
fixation through a higher aliphatic alcohol. A molecular coordination complex is formed 
between a cellulose polymer and a substituted aliphatic alcohol. The result is a 
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complex that can be utilized as a matrix for controlled drug release. The complex has a 
uniform porosity which may be varied (Leslie, 1986). This technology is employed in 
the long-acting bronchodilator Uniphyl®. Although CONTIN® technology functions as a 
conventional sustained release matrix system research suggests that evening 
administration demonstrates an improved lung function as compared to patients taking 
Uniphyl® twice daily. When taken at night, Uniphyl® causes THP blood levels to peak 
during the early hours of the morning when lung function is known to dip, making this 
the first commercial product to be indirectly used a chronopharmaceutical (Leslie, 
1986, Arkinstall, 1988).  
 
2.4.2 Pulsincaps® 
Pulsincaps® technology (Catalent Pharma Solutions, New Jersey, USA) consists of a 
water insoluble capsule body filled with drug. The capsule body is sealed with a 
swellable hydrogel plug. The plug comprises polymers such as poly (methacrylates), 
hydroxypropylmethylcellulose (HPMC), polyvinyl alcohol (PVA), polyvinyl acetate, 
polyethylene oxide (PEO), saturated polyglycolate d-glycerides, glyceryl monooleate 
and pectin (PEC) (Shweta et al., 2006; Gazzaniga et al., 2008). The capsule is coated 
with an enteric layer that dissolves upon reaching the small intestine. Upon exposure 
of the capsule to the intestinal fluid, swelling of the plug takes place which creates a 
lag-time. The plug then expands and is pushed outward and drug release occurs. The 
dimension or length of the plug and its point/depth of insertion determines the lag-time 
before drug release (Ross et al., 2000; Verma and Garg, 2001; Shweta et al., 2006; 
Anal, 2007; Patel et al., 2007, Gazzaniga et al., 2008). This technology allows one or 
more minitablets, coated tablets, solutions, or multiparticulates to be loaded within the 
capsule body (Shweta et al., 2006).  
 
2.4.3 Chronotopic® 
The Chronotopic® system provides delayed, time-dependent pulsatile delivery as well 
as colon specific release. The system comprises a drug-loaded core coated with 
HPMC. The HPMC undergoes a glassy-rubbery transition when in contact with 
aqueous fluid. Drug is then released across the gel-layer either by diffusion and/or 
erosion. The onset of action and lag-time are controlled by the thickness and viscosity 
grade of the HPMC employed during formulation (Sangalli et al., 2001; Sangalli, 2004; 
Patel et al., 2007). Furthermore, the application of a gastro-resistant film onto the 
polymer coated core of the system overcomes the variability in gastric transit-time and 
allows for colon-specific drug release (Gazzaniga et al., 1994; Gazzaniga et al., 1995; 
Sangalli et al., 2001; Shweta et al., 2006). The film allows the system to stay intact until 
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reaching the intestine where it eventually erodes and exposes the HPMC layer to the 
intestinal fluid, thus allowing the system to be pH-responsive. The tablets are prepared  
by first granulating the drug with a range of excipients which is then compressed. A 
mixture of HPMC and poly (ethylene glycol) (PEG) solutions are then sprayed onto the 
core and allowed to dry. A coating of Eudragit® is then applied onto the outer surface of 
the tablets (Sangalli et al., 2001). 
 
2.4.4 CEFORM® 
CEFORM® technology (Biovail Corporation, Ontario, Canada) involves the production 
of microspheres that are uniform in shape and size. The microspheres have a diameter 
ranging from 150-180µm and have a high drug-loading capacity. They may be applied 
in a wide variety of drug delivery systems including capsules suspensions, tablets, 
effervescent tablets and sachets (Verma and Garg, 2001: Youan, 2004; Shivakumar et 
al., 2006). This technology involves subjecting biodegradable polymers or bioactive 
agents to a combination of temperature, thermal gradients, mechanical forces, flow 
and flow-rates during processing. CEFORM® technology has been used to develop the 
chronopharmaceutical Cardizem® LA which is a once-daily DTZ formulation (Youan, 
2004). 
 
2.4.5 TIMERx® 
Penwest Pharmaceutical Company (Danbury, Connecticut, USA) has developed 
SyncroDose™ using Penwest’s TIMERx® patented matrix. This enables drugs to be 
delivered after predetermined lag-times to coincide with the body's circadian rhythm or 
to allow drugs to be delivered to different sites within the gastrointestinal tract. The 
developed SyncroDose™ tablet consists of an inner core of drug and a surrounding 
compression coating (Figure 2.2). The TIMERx® matrix system comprises xanthan 
gum, a semi-synthetic bacterial polysaccharide and locust bean gum and a plant 
polysaccharide. These polysaccharides interact synergistically with secondary and 
tertiary components (Tobyn et al., 1995; Mu et al., 1996). A ratio of between 1:3 or 3:1 
of xanthan gum to locust bean is preferably employed. A possible mechanism for the 
interaction between the xanthan gum and locust bean involves interfacing between the 
helical regions of the xanthan gum and the unsubstituted regions of the locust bean. 
This interaction allows for a high-strength gel similar to the effects of crosslinking in 
hydrogels.  
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The tablet core is prepared by wet granulation and then compressed. The TIMERx® 
matrix is prepared by blending the polymers and inert filler after which the powders are 
wet-granulated. The moistened mass is dried and milled into granules. Compression 
coating techniques are then used to enclose the core (Tobyn et al., 1995). The 
SyncroDose™ technology is able to release drug after a predetermined lag-phase with 
maximum plasma levels achieved in 5 hours. Upon contact with gastric fluid the 
combination polysaccharides interact and swell to form a taut gel with a gradual 
eroding core from which drug is released (Kelly et al., 1996; Verma and Garg, 2001; 
Patel et al., 2007). While the outer polysaccharide core may swell, the inner drug core 
remains intact. As the tablet moves through the gastrointestinal tract through the 
pylorus and into the duodenum, the outer swellable coating undergoes erosion. After 
approximately 3.5 hours erosion of the coating is complete, exposing the drug core to 
the intestinal environment where drug is released. Inclusion of a surfactant into the 
drug core allows for immediate release of drug. Alternatively, the core may be 
formulated as a controlled release matrix allowing for sustained release. The swelling 
of the matrix also results in a reduction in the bulk density, thus providing buoyancy 
and allowing the gel-mass to float on the stomach contents. Furthermore, depending 
on the size of the original tablet matrix, the gel-mass may swell to a degree that allows 
the system to obstruct the opening of the pylorus. The physicochemical properties of 
the polymers used, for example xanthan gum may be considered to be self-buffering 
(Tobyn et al., 1995). As a result the xanthan gum is not sensitive to pH variations along 
the gastrointestinal tract. Xanthan gum also has mucoadhesive properties allowing the 
drug delivery system to be retained in the stomach.  
 
Figure 2.2: Diagrammatic illustration showing Penwests Synchrodose™ formulation 
using the patented TIMERx® matrix (Adapted from www.penwest.com).   
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2.4.6 OROS® 
An OROS® osmotic pump patented by DURECT Corporation (California, USA) utilizes 
an osmotic mechanism to provide pre-programmed, controlled drug delivery. This drug 
delivery system comprises a drug compartment, a push compartment and a semi 
permeable membrane (Figure 2.3). The drug compartment is made up of drug and 
PEO granulated with a solution of poly (vinyl pyrolidine) (PVP). The push compartment  
comprises PEO, HPMC, sodium chloride and black ferric oxide which is granulated 
with HPMC. The drug compartment and the push compartment are then compressed 
into a bi-layered core. The entire core or only the drug compartment is sub-coated with 
a 95% hydroxyethylcellulose (HEC) and 5% PEG solution. This facilitates a drug-free 
interval of 2-5 hours. Thereafter, the sub-coated drug core is coated with a semi-
permeable membrane comprising 60% cellulose acetate, 35% hydroxypropylcellulose 
(HPC) and 5% PEG. An orifice is then drilled into the outer and inner cores to connect 
the drug layer with the exterior of the drug delivery system. Finally the osmotic pump is 
dried for 96 hours to remove residual solvent and a further 2 hours to remove any 
excess moisture.  
 
Drug release takes place due to the influx of fluid across the semi-permeable 
membrane into the push compartment. The increase in osmotic pressure forces drug 
to be diffused through the microscopic orifice. This drug delivery system provides a 
uniform non-varying rate of drug release allowing blood concentrations to be 
maintained within narrower limits for longer periods (Swanson et al., 1987). In addition, 
the release mechanism is less vulnerable to changes within the gastrointestinal tract 
due to the semi-permeable membrane being permeable to only water thus facilitating 
pH-independent drug release (John, 1990). This technology was employed in 
formulating the chronopharmaceutical, Covera-HS® (verapamil), an antihypertensive. 
The product facilitates delayed overnight drug release to prevent the dangerous surge 
in blood pressure that happens during the early morning. While this system has been 
applied to products, it has its limitations. Manufacturing has proved to be complicated 
with the need for a laser-drilled hole in the semi-permeable coating. In addition, 
clogging of the hole may limit drug release. Drying time also poses a challenge as the 
drug delivery system requires 4 days of drying time.  
  
 
22 
 
 
Figure 2.3: Schematic portraying the mechanics of OROS®. 
 
2.4.7 CODAS® 
Chronotherapeutic Oral Drug Absorption System (CODAS®) manufactured by Elan 
Corporation (Florida, USA) is a multiparticulate drug delivery system that provides a 
delayed onset of drug release, resulting in release that more accurately compliments 
circadian rhythms. This drug delivery system comprises a drug core and a multilayered 
membrane surrounding the core. Both the core and the multilayered membrane 
comprise water soluble and water insoluble polymers. When the bead is exposed to 
water, the water-soluble polymer dissolves and drug diffuses through the pores present 
in the coating (Figure 2.4). The water-insoluble polymer acts as a barrier and maintains 
the release of the drug (Kendall et al., 1980; Youan, 2004). The CODAS® technology 
has been applied to the chronopharmaceutical Verelan® PM (verapamil). This 
formulation is designed to release verapamil 4-5 hours after ingestion. When taken at 
bed-time, a maximum plasma concentration is achieved in the early hours of the 
morning when blood pressure is known to rise (Smith, 2001).  
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Figure 2.4:  Diagrammatic representation illustrating the concept of CODAS® 
technology. 
 
2.4.8 Diffucaps® 
Diffucaps® manufactured by Eurand Pharmaceuticals (Pennsylvania, USA) is a 
multiparticulate drug delivery system that delivers drug according to the body’s 
circadian rhythms (Roos, 2002). Drug is layered onto a neutral core which may 
comprise an inert particle such as sugar spheres, crystals or granules. An inert binder 
is used to bind the drug particles to the inert core (Figure 2.5). Examples of such 
binders include PEO, HPMC, HPC and PVP. Drug particles are dissolved or 
suspended in a 5-10 % solution of binder. The drug core is then coated with a 
plasticized enteric coating and thereafter coated with a mixture of water insoluble and 
enteric polymers. Examples of water insoluble polymers include ethylcellulose (EC), 
polyvinyl acetate and methacrylate polymer such as Eudragit® RS. Enteric polymers 
include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate and 
shellac. In order to separate the various layers a thin layer of HPMC is typically used 
(Prisant et al., 2000). The beads produced are small (<1mm in diameter) and by 
combining different beads, a combination release profile can be achieved. An organic 
acid comprising a membrane layer may optionally be added between the second and 
third coating in order to further modulate the lag-time. This technology also allows 
combining two or more drugs in order to increase patient compliance and has been 
used to produce a chronopharmaceutical product known as InnoPran® XL.  
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Figure 2.5: Schematic diagram illustrating the various layers surrounding a Diffucaps® 
bead (Adapted from www.eurand.com/Tecnologies/Controlling-Drug- 
Release/Diffucaps).  
 
2.4.9 Egalet® 
Egalet® (Egalet a/s, Copenhagen, Denmark) technology uses erosion instead of 
diffusion to control drug release. This technology has potential in chronotherapeutics 
and consists of an impermeable shell with two lag plugs enclosing a core of drug 
(Figure 2.6) (Washington and Wilson, 2006). The lag-phase is dependent on the length 
and the composition of the plugs. The impermeable shell comprises EC and 
cetostearyl alcohol, whereas the plug consists of PEG and PEO (Washington and 
Wilson, 2006). The matrix is designed to erode upon contact with the gastrointestinal 
fluid, though gastric fluid should not diffuse in the system until the point of release. This 
reduces hydrolysis and luminal enzymatic activity. A balance should exist between 
erosion and diffusion such that the surface area exposed to the dissolution media is 
constant ensuring zero order drug release (Washington and Wilson, 2006). This design 
also allows for more than one drug to be combined in a single drug delivery system. 
Varying the outer plug different release profiles may be achieved.  
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Figure 2.6: Schematic outlining the mechanics of the Egalet® Time Release System 
(Adapted from www.egalet.com/technology_timerelease.aspx). 
 
2.4.10 CHRONOSET™ 
CHRONOSET™, an ALZA Corporation (California, USA) product is an OROS® drug 
delivery system that is designed to deliver more than 80% of drug within 15 minutes in 
a time or site specific fashion (Wong et al., 1995; Dong et al., 1999). This technology 
protects the drug from chemical and enzymatic degradation before release. In addition, 
the timing of drug release is unaltered by stomach contents. The CHRONOSET™ drug 
delivery system comprised of two compartments i.e. the drug vessel and the osmotic 
cap (Figure 2.7). On exposure to aqueous media, water enters the osmotic cap via the 
rate-controlling membrane leading to expansion of the osmotic compartment. This 
expansion exerts a force against the drug vessel enabling the two compartments to 
detach exposing drug to the dissolution media enabling release of the entire dose. 
Polymers utilized in this dosage form include ethylene-co-vinyl acetate copolymer, 
water-permeable blends of polycaprolactone and flux enhancers.  
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Figure 2.7: Schematic depicting the release of drug from the CHRONOSET™ drug 
delivery system. 
 
2.5 Emerging Advances in Oral Chronotherapeutic Drug Delivery Technology 
 
The search for innovative drug delivery systems applicable to chronotherapy is ensuing 
with increasing intensity. Below are some promising drug delivery devices that may 
have application in chronotherapy. Lee et al., (1999) developed a HPMC tablet matrix 
comprising an inner drug core and an outer drug coating. The inner drug core was 
prepared using direct compression of the drug and polymer. The core was then coated 
with a drug containing aqueous-based polymeric Eudragit® RS30D dispersion. The 
tablet was able to provide a biphasic release profile with an initial zero-order release 
followed by a second sustained phase of drug release. The tablet was ineffective in 
providing a lag-phase.  
 
Dashevsky and Mohamad (2006) introduced a pulsatile rupturable drug delivery 
system consisting of a drug core, a swelling layer comprising a super-disintegrant and 
binder, and an insoluble polymeric coating comprising ethylcellulose. Drug was layered 
onto sugar pellets followed by layering with either 5% suspension of croscarmellose 
sodium, low-substituted HPC or sodium starch glycolate in a 2% HPC solution. The 
beads were coated with aqueous ethylcellulose dispersion. Fluid entered the system 
and triggered swelling causing the outer membrane to rupture resulting in drug release. 
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Drug release comprised a lag-time that was determined by the coating layer followed 
by rapid drug release indicating sigmoidal drug release.  
 
Efentakis et al., (2006) developed a drug delivery system based on core-in-cup 
technology. The device comprised of a drug containing core tablet an outer 
impermeable layer and a top cover. The bottom and the circumference wall comprised 
an inactive material which surrounded the drug core. The core comprised cellulose 
acetate propionate. The top layer comprised a soluble polymer such as sodium 
carboxymethylcellulose, sodium alginate and PEO. Upon contact with dissolution 
media, the top cover absorbs fluid and swells creating a barrier between the dissolution 
media and the inner drug containing core. The time taken for the swollen layer to erode 
determines the lag-time. Once the top layer has eroded drug release occurs. Drug 
release from this formulation displays a lag-phase between 50-245 minutes depending 
on the type of polymer and drug used. Drug is then rapidly released so that drug is 
released in a sigmoidal manner.  
 
Karavis et al., (2006) developed a bilayered tablet that provided a lag-phase followed 
by drug release. The bi-layered tablet makes use of felodipine and PVP as a drug core 
and a HPMC/PVP blend surrounding the core. The combination of HPMC and PVP 
served to enhance the mucoadhesive properties of the tablet. Upon exposure to 
dissolution media the outer layer disintegrated exposing the core to the gastric 
contents thus allowing the release of drug. The lag-time was dependent on the 
swelling/erosion of the HPMC/PVP matrix. Varying the ration of the HPMC to PVP 
affected the lag-time. 
 
Sher et al., (2007) made use of floating and pulsatile technology in order to develop a 
chronotherapeutic drug delivery system that may be employed in the treatment of 
cancer. This was achieved with no excipient, low-density, microporous beads loaded 
with ibuprofen. Drug was loaded onto porous Accurel MP 1000® microparticles using 
melt and solvent evaporation techniques. The microparticles were tested for 6 hours in 
pH 1.2 followed by 3 hours in pH 7.2. Drug release proved to be minimal while floating 
in the stomach followed by a burst of drug release at a pH of 7.2. Similar results were 
obtained by Badve et al., 2007 where hollow porous calcium pectinate beads were 
developed. In vivo studies conducted on rabbits demonstrated promising results with 
gastric floatation lasting for 5 hours. 
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 A novel drug delivery system based on a ―tablet in capsule device‖ capable of 
producing up to three pulses of drug release, has been developed by Li et al., (2008). 
The device comprises a water soluble cap, impermeable capsule body, and two multi-
layered tablets which are filled within the capsule body and sealed with a water-soluble 
cap. The capsule is also filled with lactose and a modulating barrier layer (Figure 2.8).  
 
 
Figure 2.8: Diagrammatic representation of the tablet in capsule device (Adapted: Li et 
al., 2008). 
 
The impermeable capsule comprises EC while the rapid release layer comprises 
crospovidone and lactose. HPMC, sodium alginate, carbopol and 
carboxymethylcellulose were evaluated for use as the modulating barrier, with alginate 
and HPMC displaying the best results. The drug release profile achieved by this device 
displays three phases of drug release within a 12 hour period. By manipulating the 
quantity of polymer in the barrier layer, the lag-phase between the pulses can be 
controlled. A difference in lag-time was observed when the tablets were inserted into 
various locations within the capsule body. Although this technology allows for the 
combining of three doses into a single system, the manufacturing process might prove 
time consuming as each component of the device is prepared separately. 
 
Enteric-coated microspheres were developed for colonic drug delivery by Maestrelli et 
al., (2008). These calcium pectinate microspheres may be applied to 
chronotherapeutic disorders as well as for local treatment of the colon. The 
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microspheres were formed by homogeneously dissolving PEC in distilled water and 
then adding drug. The dispersion was then passed through a nozzle into a solution of 
calcium chloride. The microspheres were formed immediately by ionotropic gelation. 
Coating of the microspheres involved immersing the spheres in a solution of Eudragit® 
S100 and allowing them to dry by solvent evaporation. Drug release studies were 
performed in pH 1.1, 6.6 and 7.4. Results obtained from the study displayed negligible 
drug release at pH 1.2, <10% drug release in simulated intestinal fluid followed by 
complete release in the colon. Though this drug delivery device produces an initial lag-
phase it does not provide pulsatile drug release.  
 
Chitosan microspheres were developed by Jose et al., (2011) with the purpose of 
creating a chronotherapeutic colon specific DTZ dosage form for use in the treatment 
of stable angina. The microspheres were developed by emulsion cross-linking of 
chitosan and coated with Eudragit S-100 by solvent evaporation techniques. DTZ was 
encapsulated within the microspheres. Non-coated microspheres displayed a burst 
release whereas coated microspheres displayed controlled release suggesting that the 
Eudragit® coating protects the DTZ from release below a pH of 7.  
 
These technologies do have their limitations mainly due to their complicated 
manufacturing procedures. In addition, multiparticulates have not been extensively 
tested in humans where they may behave in a very different manner to that exhibited in 
vitro. In terms of the drug release profiles achieved only the ―Tablet in Capsule Device‖ 
was able to provide more than one pulse of drug release.  
 
2.6 Parenteral Chronotherapeutic Drug Delivery Systems 
 
Examples of parenteral drug delivery systems that are indicated for chronotherapeutic 
use include the chronomodulated infusion pumps: Melodie® (Laboratoire Aguettant, 
Lyon, France), Synchromed® (Medtronic, Minneapolis, USA) and Rhythmic® (Micrel 
Medical Devices, Athens, Greece). With these pumps frequency, timing and order of 
drug administration can be programmed.  
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2.7 Concluding Remarks 
 
The concept that the body is in a constant homeostatic equilibrium is no longer true 
according to the literature. Evidence suggests that the bodies’ internal clock alters 
homeostatic control during a 24 hour period leading to fluctuations in certain integral 
processes such as blood pressure control, cortisol release and gastric acid secretion. 
With the identification of numerous conditions that follow a circadian rhythm, a superior 
understanding of chronotherapy is required in the medical and pharmaceutical fields. 
As numerous drugs are influenced by the daily time-scale, it is disconcerting that so 
few chronopharmaceuticals exist on the market. To date, no drug delivery system is 
able to satisfy all the requirements of chronotherapeutics. The search for innovative 
drug delivery systems applicable to chronotherapy is ensuing with increasing intensity. 
Extensive research in this field is a necessity in order to improve patient outcomes with 
research going as far as human studies.  
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CHAPTER THREE 
PRELIMINARY STUDIES INTO THE DEVELOPMENT OF THE MULTI-LAYERED 
MULTI-DISK TABLET 
 
 
3.1 Introduction 
 
The use of hydrophilic matrices in controlling the release rate of drugs from solid 
dosage forms has become increasingly popular. Examples include Matsuo et al., 1996; 
Roy and Rohera, 2002; Wu et al., 2005; Conti et al., 2006; Jamzad and Fassihi, 2006; 
Khairuzzaman et al., 2006; Hardy et al., 2007. The use of such water swellable 
polymers allows for the formation of a viscous gel layer as the surface of the polymer 
hydrates when exposed to dissolution media. The viscous gel layer is a diffusional 
barrier that retards further water uptake and the release of the dissolved drug. Verma 
et al., (2004), have reported that the gel layer formation and its stability define the 
kinetics of drug delivery from matrix systems. This is controlled by the concentration, 
viscosity and chemical structure of the polymer. Conti et al., (2006), have reported that 
cellulose ethers are probably the most commonly used water soluble polymers in 
pharmaceutical text. Cellulose ethers have the advantage of being non-toxic, cost 
effective, having good compressibility and swelling characteristics and are able to 
accommodate a large percentage of drugs. Furthermore, they are FDA approved and 
as such can contribute to shorter approval times.  
 
To formulate a successful hydrophilic system a polymer needs to be chosen that will 
wet, hydrate and swell to form a gel layer fast enough to prevent disintegration of the 
tablet. The rapid formation of a gel layer is critical to prevent wetting of the interior and 
disintegration of the tablet core. As water penetrates the system, the outer layer gels 
and swells while the core remains dry. The region between the gel layer and dry core 
is known as the rubbery region (Figure 3.1). Once the gel layer forms it controls the 
penetration of additional water into the tablet. The gel layer dissolves due to a 
decrease in the viscosity of this gel and a new inner layer must replace it and must be 
cohesive and continuous enough to retard the influx of water and control drug diffusion. 
Although gel strength is controlled by polymer viscosity and concentration, polymer 
chemistry also plays a significant role. HPMC is thought to encourage a strong tight gel 
formation compared to other cellulosic polymers. As a result, drug release has been 
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sustained longer with HPMC than with the same quantity of methylcellulose, HEC, 
HPC and carboxymethyl cellulose. Thus, HPMC has been chosen for use in the rate 
controlling outer layers of this drug delivery system.  
 
 
Figure 3.1: Schematic depicting a matrix tablet at a) T0 and b) after exposure to 
dissolution media. 
 
Of the cellulose ethers, HPMC is the most widely studied hydrophilic swellable polymer 
(Li et al., 2005; Khairuzzaman et al., 2006). HPMC is derived from alkali-treated 
cellulose by reacting with methyl chloride and propylene oxide. It is non-ionic and 
minimizes interactions when used in acidic, basic or other electrolyte systems. It offers 
the convenience of swift hydration, excellent compressibility, superior gelling and low 
toxicity.  
 
Other cellulose ethers used in this study include EC and HEC. HEC is a cellulose of 
short to very long chain length that is non-ionic in nature thus allowing pH-independent 
drug release. EC is a hydrophobic cellulose in which the backbone is based on 
repeating anhydroglucose units. EC offers the benefits of being non-toxic, inert and 
stable at various pH values. Uses include coating (Li et al., 2010; Rujivipat and 
Bodmeier, 2010; Terebesi and Bodmeier, 2010; Zhao et al., 2010), pellets and spheres 
(Frohoff-Hϋlsmann et al,. 1999; Kranz and Gutsche, 2009; Shi et al., 2009), tablets 
(Mäki et al., 2006; Abdel-Rahman et al., 2009; Quinten et al., 2009). 
 
This chapter addresses the selection of polymers that led to the development of the 
MLMDT. A comparative analysis of polymers is performed as these tests are critical in 
obtaining the desired release profile. In-process validation of the developed MLMDT’s 
was assessed determining the suitability of the devices components. 
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3.2. Material and Methods  
 
3.2.1 Materials 
Polymers utilized in the study include: HPMC (Methocel® K4M CR, Colorcon Limited, 
Kent, United Kingdom), HPC (Klucel®, EF Pharm, Hercules Inc., North Carolina, USA), 
HEC (viscosity 4000mPas, Merck Schuchardt, Hohenbrunn, Germany), PEO (Polyox 
N12K®, molecular weight approximately 1x106g/moL, viscosity range 400-800cps, Dow 
Chem. Corp., Michigan, USA), poly(lactic-co-glycolic acid) (PLGA) (Resomer RG504, 
molecular weight 55,000g/moL, Boehringer Ingelheim GmbH, Ingelheim, Germany), 
EC (48-49.5% ethoxy content, viscosity 11cP, Sigma-Aldrich , Missouri, USA), PEC Cu 
701 (Degree of esterification 38%, molecular Weight 80, Herbstreith and Fox, 
Neuenburg Germany), Alginate (Protanal® LF 10/60, FMC BioPolymer, Haugesund, 
Norway), PVA (molecular weight 49,000g/moL, Sigma-Aldrich, Missouri, USA). The 
model drugs THP (solubility 1-5mg/mL) and DTZ (solubility > 50%) were purchased 
from Sigma-Aldrich (Missouri, USA). Surelease® (EC aqueous dispersion) and 
Sureteric® (polyvinyl acetate phthalate) (PVAP) (Colorcon Limited, Kent, United 
Kingdom) were employed as granulating fluid. Other excipients include Avicel® (AVC) 
(Microcrystalline cellulose, FMC BioPolymer, Haugesund, Norway), Lactose and 
Sodium Bicarbonate (Saarchem, Krugersdorp, South Africa). Lactose was used as a 
bulking agent in Disk 1.  
 
3.2.2 Preparation of Disk 1 (D1) 
Lactose and either THP (15mg) or DTZ (18mg) were measured, blended and directly 
compressed using a Karnavati Mini Press II (Rimek Products, Gujarat, India) loaded 
with a 10mm in diameter punch and die. The quantity of drug in this disk comprised 
30% of the total drug utilized in the MLMDT. 
 
3.2.3 Preparation of Disk 2 (D2)  
Quantities of drug (70% of total drug utilized in the entire device) and polymer were 
granulated by wet granulation, with Surelease®, Sureteric® or a combination of these 
used as a granulating fluid (where applicable). Where no granulating fluid was utilized, 
polymer and drug were directly compressed. Surelease® was prepared as per 
manufacturer instruction by measuring a 60% w/v of the solution and adding 40% w/v 
of deionized water (Milli-Q Millipore, Massachusetts, USA). The solution was then 
agitated for 40 minutes prior to use. Sureteric® was reconstituted to a 15% solid 
suspension using deionized water (Milli-Q Millipore, Massachusetts, USA) to which 
0.33% of an antifoaming agent was added. The suspension was agitated for 30 
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minutes prior to use. Drug and polymer were blended using a cube blender (Erweka 
Apparatebau, Heusenstamm, Germany) to which the granulating fluid was then added 
to produce a wet mass. The wet mass was then passed through a 2000mm aperture 
sieve and collected. The granules were placed in an oven at 37°C until dry. The 
granules were weighed and compressed using a Karnavati Mini Press II.  
 
3.2.4 Preparation of the final MLMDT 
A schematic of the MLMDT is highlighted in Figure 1.3, Section 1.2, Chapter 1. Briefly, 
the outer drug-free polymeric layers comprised three barrier layers (L1, L2 and L3) in 
which the disks were enveloped. DTZ formulations contained sodium bicarbonate 
(where applicable). Table 3.1 and 3.2 expands on the specific quantities utilized. In 
order to combine the device, L1 was added to a flat-faced 13mm punch and die and 
after leveling out the powder D1 was inserted and then centered using the tip of a 
needle. The next layer (L2) was then incorporated and leveled followed by the 
placement and centering of D2 and lastly L3. The punch was then inserted and the 
device was compressed at 5 tons using a Beckman hydraulic tablet press (Beckman 
Instruments, Inc., California, USA). To minimize processing variables, all the devices 
were produced under identical conditions.  
  
 
 
 Table 3.1: Mass constituents utilized in the preformulation of the THPa-loaded MLMDT’s. 
b
 
Total quantity loaded=50mg with 15mg loaded in D1 and 35mg loaded in D2.  
b
: 1mL of Granulating Agent was utilized per formulation   
 D1 D2 Barrier Layers Granulating Agent 
Formulation Lactose (mg) Polymer 
(70mg) 
L1 (50mg) L2 
(100mg) 
L3 
(200mg) 
Surelease® 
(EC)b 
Sureteric® 
(PVAP) b 
1 30 EC Alginate PEO PLGA - - 
2 30 PLGA PEC HEC HEC - - 
3 30 PLGA PEC PEO PEO - - 
4 30 HPMC PEC HPMC HPMC - - 
5 30 EC PEC HPMC HPMC - - 
6 30 EC PEC Alginate Alginate - - 
7 30 PLGA/PVA (1:3) PEC HPMC HPMC 1mL - 
8 145 EC PEC HPMC HPMC 1mL - 
9 145 PVA PEC HPMC HPMC 1mL - 
10 145 EC/HEC (1:1) PEC HPMC HPMC 1mL 1mL 
 
 
 Table 3.2: Mass constituents utilized in the preformulation of the DTZa-loaded MLMDT’s.  
a:
 Total quantity of drug loaded=60mg with 18mg loaded in the first disk and 42mg loaded in the second. 
b
: 1mL of Granulating Agent was utilized per formulation 
c
: Sodium Bicarbonate added in D2.  
 Disk One Disk Two Barrier Layers Granulating Agent 
Formulation Lactose (mg) 
Polymer 
(84mg) 
L1 
 (150mg) 
L2  
(100mg) 
L3 
 (200mg) 
Surelease® 
(EC)b 
Sureteric® 
(PVAP) b 
11 142 EC PEC HPMC HPMC - 1mL 
12 142 HEC/EC (1:3) PEC HPMC HPMC 1mL - 
13 142 HEC/EC (4:1) PEC HPMC HPMC 1mL - 
14 142 EC PEC HPMC HPMC 1mL - 
15c 142 HEC/EC (1:3) PEC HPMC HPMC 1mL - 
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3.2.5 In vitro drug release studies 
The in vitro drug release studies were carried out using USP dissolution apparatus II 
(Erweka, Heusenstamm, Germany) equipped with paddles. Dissolution was performed 
in 900mL simulated human gastrointestinal fluid (SHGF) pH 1.2 (Table 3.3) (Lee et al., 
1999) for the first 2 hours and simulated human intestinal fluid (SHIF) pH 6.8 (Table 
3.3) (Giannola et al., 2007) for the remainder of the study. Where sodium bicarbonate 
was used, formulations were tested in pH 1.2 due to floatation of the formulation. The 
devices were placed on a ring wire-mesh assembly as formerly carried out by Pillay 
and Fassihi (1999). The wire mesh fits into the lower portion of the glass vessels and 
prevents the device from sticking to the bottom of the vessel, allowing the full surface 
area of the device to be exposed to the dissolution medium. Dissolution was carried 
out at a speed of 50 rpm and at a temperature of 37±0.5°C. Sampling of 5mL was 
carried out every 1 hour for 12 hours and thereafter at the 24th hour. The withdrawn 
amount of sample (i.e. 5mL) was replaced with an equal amount of the simulated fluid 
such that the volume of the simulated fluid in the dissolution medium remained 
constant. The drug content was analyzed by Ultra Violet (UV) spectrophotometer 
(Hewlett Packard 8453, Boeblingen, Germany) at λ280nm for THP and λ238nm for DTZ and 
computed from a standard linear curve of drug in SHGF and SHIF (R2>0.99).  
 
Table 3.3: Constituents used to prepare the simulated human gastric fluid (SHGF) and 
simulated human intestinal fluid (SHIF). 
Component SHGF (pH 1.2)a SHIF (pH 6.8)b 
 (Quantity in 1L) (Quantity in 1L) 
KH2PO4 -                   0.144g 
Na2HPO4 - 0.795g 
NaCl 2.0g  9.000g 
HCl (Conc) 7mL - 
a
Simulated human gastric fluid (Lee et al., 1999) 
b
Simulated human intestinal fluid (Giannola et al., 2007) 
 
3.2.6 Construction of calibration curves for spectrophotometric determination of 
THP and DTZ 
Calibration curves for THP and DTZ was constructed using a known series of 
concentrations of THP and DTZ (0 to 0.025mg/mL). Using simulated fluid as a blank, 
the absorbance of each solution was measured and a linear curve was plotted with the 
observed absorbance on the y-axis and concentration (mg/mL) on the x-axis. The 
correlation coefficient was also calculated.  
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3.2.7 Assessment of the friability of the disks and the MLMDT  
Friability was performed on both disks as well as the compressed MLMDT. A sample of 
10 units was examined to ensure reproducibility of the tablet making process. Analyses 
were determined on a Friabilator (Erweka D-63150, Heusenstamm, Germany) at 
25rpm for 4 minutes with 1% set as the upper limit of acceptability. The weight of each 
device was determined using an analytical digital balance (Mettler, Model AE 240, 
Griefensee, Switzerland) with readings recorded to 2 decimal places. The friability was 
expressed in terms of weight loss and was calculated in % (% ±SD) of the initial 
weight. 
 
3.2.8 Assessment of the powder and granule flowability 
The flowability of both the granules and the combination of powders used for both 
disks was studied. Carr’s index, angle of repose and Hausner ratios were used to 
determine powder flow. Carr’s index and Hausner ratio were calculated from the bulk 
and tapped density via the tapping method. A cylinder, to which a known quantity of 
powder or granules was added, was subjected to a fixed number of taps. The final 
volume after tapping was recorded and calculated using the equations below: 
 
              Equation 3.1 
    
 
              Equation 3.2 
 
The angle of repose (θ) was calculated using the fixed funnel method. A glass funnel 
was secured with its tip positioned at a fixed height (H) above graph paper placed on a 
horizontal surface. The sample was poured through the funnel until the apex of the 
conical pile touched the tip of the funnel. The angle of repose was calculated using the 
formula below: 
 
                   Equation 3.3 
 
where θ is the angle of repose and R is the radius of the conical pile. 
Carr  's   index ( %)  = 
Tapped - Poured   density 
Tapped   density 
×100  
Hausner Ratio= 
Tapped density ( ρ        ) max 
Poured density ( ρ        )   min 
 ×100   
tan θ=  
H 
R 
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3.3 Results and Discussion 
 
3.3.1 Calibration curves for the determination of drug concentration 
Standard solutions of both model drugs, THP and DTZ, were prepared by separately 
mixing known concentration of each drug in simulated gastric fluid. The standard 
solutions employed in preparing the calibration curve of the drugs were obtained by 
serial dilutions with a final concentration ranging between 0.005-0.025mg/mL. Figure 
3.2 illustrates the calibration curves for THP and DTZ employing a UV spectrometer at 
λ280nm for THP and λ238nm for DTZ.  
 
Figure 3.2: Calibration curves for a) THP at 280nm and b) DTZ at 238nm (N=3; SD 
<0.01 in all cases).  
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3.3.2 In vitro drug release analysis from THP-loaded MLMDT’s  
Drug is released after a lag-phase from D1 corresponding to the first pulse of release. 
The remaining layers, L2 and L3, control the rate of release from D2. These layers 
should ideally protect drug from release for approximately 8-12 hours to allow for the 
―switch-off‖ phase, and then only should drug be released from D2. Theoretically 
release should not occur from both disks at the same time. A schematic of this process 
is highlighted in Figure 3.3. 
 
 
Figure 3.3: Schematic depicting the ideal drug release profile required from the 
MLMDT. 
 
Figure 3.4 (a-c) depicts the drug release profiles from the 10 THP formulations. All 
release profiles display biphasic release with an initial lag-phase. The first pulse 
provides rapid drug release while the second pulse displays sustained release. The 
rate at which drug is released during the second pulse is governed by the L2, L3 and 
D2. F5 and F8 (Figure 3.4a) displayed minimal drug release from D2 (38% and 32% 
respectively) due to the hydrophobic nature of EC which impedes the release of drug. 
Furthermore, combining EC with Surelease® (F8) resulted in no drug release from D2 
suggesting that this combination was too hydrophobic. 
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Figure 3.4: Drug release profiles of THP-loaded MLMDT’s: a) formulation 1 to 4; b) 
formulation 5 to 8 and c) formulation 9 and 10 (N=3; SD <0.47 in all cases). 
  
a) 
b) 
c) 
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3.3.3 In vitro drug release analysis from DTZ-loaded MLMDT’s  
Results from drug release studies performed on DTZ-loaded MLMDT’s are presented 
in Figure 3.5a-b. F11 displayed biphasic release kinetics whereas F12 presented zero-
order release indicating that both disks released drug simultaneously. F13 (Figure 
3.5a) displayed no drug release between T=5 and T=6 hours. However, drug release 
was incomplete over the 24 hours (<60%). F14 displayed an initial pulse of drug 
release, but thereafter only displayed cumulative release of 40% in the remaining 24 
hours implying that the polymer combination used was ineffective. F15 (Figure 3.5b) 
included the electrolyte sodium bicarbonate with EC and the hydrophilic HEC 
granulated with Surelease® in D2. The inclusion of sodium bicarbonate is based on 
work published by Pillay and co-workers (1999) which demonstrated that the inclusion 
of sodium bicarbonate gave rise to in situ ionic interactions resulting in the inhibition of 
drug dissolution due to a ―matrix-stiffening‖ effect. A ―switch-off‖ phase of three hours 
was observed with over 70% of drug release over the full 24 hours. Thus, the inclusion 
of sodium bicarbonate with the combination of a hydrophobic and hydrophilic polymer 
was sufficient to retard drug release so that a ―switch-off‖ phase is achieved while at 
the same time allowing for adequate drug release over the 24 hour period. With the 
remaining formulations, the polymer combinations utilized proved to be ineffective in 
producing the desired release profile. In order to produce this profile, polymers used in 
D2 are required to retard drug release for approximately 8-12 hours. Therefore, the 
polymer combination employed plays an important role in producing the desired 
release profile.  
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Figure 3.5: Drug release profiles of DTZ-loaded MLMDT’s: a) formulation 11-13 and b) 
formulation 14 and 15 (N=3, SD<0.02 in all cases). 
 
3.3.4 Analysis of the disk and MLMDT friability  
Table 3.4 illustrates the friability (expressed as a percentage) of D1, D2 and the 
complete MLMDT device. Formulations 1-7 demonstrated values ranging between 
11.0 and 12.1% for D1 indicating the disks were extremely friable. To decrease the 
friability, the quantity of lactose incorporated into D1 was increased from 30mg to 
145mg (F8-F15). This decreased the friability to within the acceptable range of <1% 
and had no significant impact on drug release. Friability values of D2 all fall within the 
desired range. Granulated disks (Formulation 6 onwards) revealed lower friability than 
the directly compressed disks (Formulation 1-6). Friability values of the complete 
MLMDT all met the necessary requirements and fall within the acceptable range.  
  
b) 
a) 
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Table 3.4: Table displaying the friability values of the fifteen formulations.   
Formulation D1 (%±SD) D2 (%±SD) MLMDT (%±SD) 
 
1 11.251 ± 0.015 0.621 ± 0.014 0.475 ± 0.005 
2 12.015 ± 0.021 0.611 ± 0.009 0.675 ± 0.009 
3 11.425 ± 0.016 0.651 ± 0.015 0.401 ± 0.011 
4 11.502 ± 0.024 0.677 ± 0.019 0.367 ± 0.017 
5 12.102 ± 0.017 0.658 ± 0.017 0.354 ± 0.014 
6 11.963 ± 0.024 0.641 ± 0.012 0.322 ± 0.017 
7 11.547 ± 0.020 0.511 ± 0.011 0.360 ± 0.021 
8 0.854 ± 0.027 0.498 ± 0.021 0.346 ± 0.018 
9 0.795 ± 0.014 0.533 ± 0.009 0.351 ± 0.014 
10 0.80 ± 0.029 0.554 ± 0.017 0.339 ± 0.010 
11 0.815 ± 0.014 0.578 ± 0.018 0.351 ± 0.019 
12 0.837 ± 0.012 0.521 ± 0.023 0.301 ± 0.012 
13 0.797 ± 0.014 0.503 ± 0.007 0.332 ± 0.008 
14 0.812 ± 0.013 0.435 ± 0.006 0.329 ± 0.014 
15 0.785 ± 0.011 0.448 ± 0.009 0.321 ± 0.013 
 
3.3.5 Analysis of the powder and granule flowability 
Table 3.5 displays the Carr Index and Hausner ratio of the disks used in the 
formulations. Poor flowability of D1 was displayed in F1-F6 as both the Carr Index and 
the Hausner Ratio are out of the normal range (< 18 and < 1.25 respectively). The 
increase in lactose (F8 onwards) decreased the values which suggested improved 
flowability. Values for D2 all fell within the acceptable range with granulated blends (F8 
onwards) displaying enhanced flowability due to the larger particle surface area. 
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Table 3.5: Carr Index and Hausner ratio of D1 and D2 in the various formulations. 
                                          
Formulation 
Carr Index Hausner Ratio 
D1 D2 D1 D2 
1 26.31 ± 0.320 12.33 ± 0.394 1.963 ± 0.008 1.073 ± 0.006 
2 28.21 ± 0.442 11.73 ± 0.493 1.895 ± 0.006 0.959 ± 0.005 
3 26.94 ± 0.393 13.01 ± 0.470 1.937 ± 0.007 1.092 ± 0.007 
4 29.12 ± 0.462 12.32 ± .349 1.824 ± 0.004 1.003 ± 0.006 
5 28.22 ± 0.511 11.90 ± 0.462 1.876 ± 0.005 1.041 ± 0.008 
6 27.39  0.401 12.67 ± 0.369 1.927 ± 0.006 1.087 ± 0.006 
7 28.39 ± 0.367 8.69 ± 0.476 1.909 ± 0.009 0.946 ± 0.004 
8 17.79 ± 0.509 6.90 ± 0.432 1.187 ± 0.008 0.917 ± 0.007 
9 17.63 ± 0.439 6.37 ± 0.561 1.197 ± 0.005 0.987 ± 0.005 
10 17.99 ± 0.591 7.21 ± 0.532 1.190 ± 0.007 0.902 ± 0.005 
11 17.93 ± 0.466 6.27 ± 0.632 1.101 ± 0.006 0.910 ± 0.004 
12 17.21 ± 0.407 7.93 ± 0.497 1.078 ± 0.003 0.937 ± 0.003 
13 18.02 ± 0.397 7.43 ± 0.367 1.117 ± 0.006 0.952 ± 0.004 
14 17.91 ± 0.409 8.13 ± 0.567 1.121 ± 0.003 0.993 ± 0.005 
15 17.29 ± .0428 6.37 ± 0.497 1.167 ± 0.004 0.949 ± 0.006 
 
3.4 Concluding Remarks 
 
A range of polymers were initially utilized to determine the effects of the polymer on 
drug release. Results from dissolution studies displayed one pulse of drug release 
suggesting that drug release occurred simultaneously from both disk. Thus, in order to 
produce the second pulse, release from D2 should be delayed. This delay is 
dependent on the polymers in D2. The combination of a hydrophobic and hydrophilic 
polymer in D2, such as EC and HEC proved to be advantageous as it slowed drug 
release in THP-loaded formulations, but still allowed for near complete drug release 
after the 24 hours. The use of a granulating fluid was also necessary as it impedes 
drug release. Due to the high solubility of DTZ, both disks released drug 
simultaneously even with the inclusion of the hydrophobic EC. The inclusion of sodium 
bicarbonate however, decreased the rate at which drug release occurred. This was 
attributed to in situ ionic interactions due to a―matrix-stiffening‖ effect. Friability, Carr 
Index and Hausner Ratio tests indicated that increasing lactose in D2 improved the 
friability of the disks and the flowability of the powders.  
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CHAPTER FOUR 
IN VITRO STUDIES AND OPTIMIZATION OF THE MULTI-LAYERED MULTI-DISK 
TABLET  
 
 
4.1 Introduction 
 
Successful development of a drug delivery system requires the delivery of the active 
ingredient in a controlled manner. In the design and characterizing of a drug delivery 
system, computer programs are becoming exceedingly popular (Ghaffari et al., 2006). 
Artificial neural networks (ANN) were introduced into the pharmaceutical field by 
Hussain et al. and coworkers in 1991. Since then ANN models were utilized in the 
prediction of drug release profiles, optimization of formulations and predicting process 
variables (Chen et al., 1999; Ibrić et al., 2002; Vaithiyalingam and Khan, 2002; 
Barmpalexis et al., 2010). This model also eliminates trial and error which proves to be 
time-consuming and inaccurate. With ANNs there is no need to assume an underlying 
data distribution. In addition, ANNs are applicable to highly non-linear multivariate 
problems (Sando et al., 2005). ANN’s are computer programs that are designed to 
replicate the learning process of the human brain (Chen et al., 1999; Sun et al,. 2003). 
The most recognized ANN types are: Multilayer Perceptron (MLP), radial basis function 
networks, linear networks, Kohonen networks and Bayesian networks (probabilistic 
and generalized regression) (Ibrić et al., 2002). 
 
The MLP overcomes the limitation of the single-layer perceptron by the addition of one 
or more hidden layer(s) (Ghaffari et al., 2006). MLPs are layered feed forward 
networks typically trained with static back propagation. These networks have found 
their way into countless applications requiring static pattern classification. Their main 
advantage is that they can approximate any input/output map. The key disadvantages 
are that they train slowly, and require lots of training data typically three times more 
training samples than network weights. Generalized Feed Forward (GFF) networks are 
a generalization of the MLP such that connections can jump over one or more layers. 
In theory, a MLP can solve any problem that a GFF network can solve. In practice, 
however, GFF networks often solve the problem much more efficiently. This study 
utilizes a GFF model to predict the release of drug from the device when the 
composition and quantity of polymer in the second disk is varied.  
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The aim of this chapter is to utilize ANNs to generate an optimized formulation and to 
evaluate the physicochemical and physicomechanical properties of the generated 
optimized formulations.  
 
4.2 Materials and Methods 
 
4.2.1 Materials 
Materials employed include those mentioned in Chapter 3, Section 3.2.1.  
 
4.2.2 Preparation of the MLMDT device 
The MLMDT was prepared according to the method provided in Chapter 3, Section 
3.2.2.1. Table 4.1 depicts the mass of the constituents of the MLMDT. 
 
Table 4.1: Mass constituents utilized in the preparation of the MLMDT device. 
 DTZ-Loaded 
MLMDT 
THP-Loaded 
MLMDT 
PEC Barrier Layer (L1) 150mg 150mg 
HPMC Middle Barrier Layer (L2)  150mg1 100mg 
HPMC Outer Barrier Layer (L3)  250mg1 200mg 
Disk 1 160mg 160mg 
Disk 2 160mg 160mg 
Total Weight of Device 870mg 770mg 
1 
The DTZ-loaded MLMDT includes an additional 100mg of sodium bicarbonate in the HPMC 
layers.  
 
4.2.3 Evaluation of the prepared disks and MLMDT 
Friability, hardness, thickness and uniformity of mass analyses were performed on 
both the disks and the final MLMDT. A sample of 10 units was examined to ensure 
reproducibility of the tablet making process. Hardness analyses were carried out on a 
Hardness Tester (Pharma Test, Hainburg, Germany) while friability was determined 
using the same instruments, parameters and limits as described in Chapter 3, Section 
3.2.2.6. A digital caliper was used to determine the thickness of the disks and the final 
MLMDT’s. 
 
4.2.4 Computational modeling to obtain an optimized formulation using the 
Artificial Neural Networks approach 
Comparative polymer studies conducted in Chapter 3, Section 3.2.2.1 highlighted the 
important polymers (HPMC, EC and HEC) and combinations thereof that would 
ultimately lead to the desired release profile. Important data generated from the above 
analysis indicated that drug release from D2 proved to be the most variable and 
therefore was fit into the ANN model to generate an optimized formulation. Based on 
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data generated in Chapter 3, Section 3.2.2.1, 21 formulations with variations in the 
quantities of HPMC, EC and HEC were evaluated for drug release. Table 4.2 depicts 
11 THP formulations while Table 4.3 illustrates 10 DTZ formulations. Although HPMC 
proved to be a suitable candidate when formulating disks for the THP devices, this was 
not the case for DTZ formulations and was thus omitted. Sodium Bicarbonate was 
evaluated for its effect on drug release in DTZ-loaded formulations and was studied in 
D2 and in L2 and L3.   
 
Table 4.2: Table depicting the polymers, granulating and bulking agents used in  
D2 of THP-loaded formulations. 
    Granulating Agent  
Formulation HEC (mg) EC (mg) HPMC (mg) Surelease
® 
 
(mL) 
Sureteric
® 
(mL) 
Bulking Agent 
(lactose) 
(mg) 
1 - - 70 - - - 
2 70 - -  0.5 0.5 - 
3 - 70 - - 1 - 
4 - 70 - 1 - - 
5 - 50 - 1 - 30 
6 - 35 - 1 - 35 
7 70 - - 1 - - 
8 - 23 - 1 - 47 
9 - - 70 1 - - 
10 35 35 - 1 - - 
11 14 56 - 1 - - 
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Table 4.3: Table depicting the polymers, granulating and bulking agents used in D2 
of DTZ-loaded formulations. 
    Sodium Bicarbonate 
Formulation HEC (mg) EC (mg) Surelease
® 
(mL) 
D2 
(mg) 
L2
 
(mg)
 
L3
 
(mg) 
12 - 84  - - - 
13 21 63 1 - - - 
14 21 63 1 50 - - 
15 21 63 1 - 50 50 
16 21 63 1 50 50 50 
17 21 63 1 - 100 100 
18 21 63 1 100 100 100 
19 21 63 1 50 - 50 
20 42 42 1 - - - 
21 21 63 1 50 50 - 
 
The data generated was fit into an ANN model, specifically the MLP, so as to generate 
an optimized formulation. MLPs are layered feed-forward networks typically trained 
with static back propagation. These networks have found their way into countless 
applications requiring static pattern classification. Their main advantage is that they 
can approximate any input/output map. The key disadvantages are that they train 
slowly and require lots of training data (typically it utilizes three times more training 
samples than network weights). The GFF network used in this study is a generalization 
of the MLP such that connections can jump over one or more layers (Figure 4.1). In 
theory, a MLP can solve any problem that a GFF network cannot solve. In practice, 
however, GFF networks often solve the problem much more efficiently.  
 
 
 
Figure 4.1: Diagram representing a Multilayer Perceptron (MLP) with two hidden 
layers. 
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For the hidden and output layers, a genetic algorithm with the Sigmoid Axon transfer 
function and Conjugate Gradient learning rule were employed. A maximum of 10 000 
epochs were run on NeuroSolutions Version 4.32 (NeuroDimension Inc., Florida, USA) 
to ensure optimal training of data.  
 
4.2.5 In vitro drug release analysis 
The in vitro drug release studies were carried out using a USP dissolution apparatus II 
(Erweka, Heusenstamm, Germany) equipped with paddles as described in Chapter 3, 
Section 3.2.2.4. Digital images of the devices at certain dissolution times were 
captured using a digital camera (Samsung NV15) to obtain changes of the devices 
during dissolution by recording the top view of the MLMDT. 
 
4.2.6 Polymer swelling studies 
The rate of test water uptake was determined by the equilibrium weight gain method as 
formerly carried out by Efentakis et al., (2000). The MLMDT’s were weighed and 
placed in a USP dissolution apparatus II as described in Section 3.2.2.2 over a period 
of 24 hours. At regular intervals the MLMDT’s were removed, blotted with tissue paper 
to remove the excess fluid and reweighed. The percentage water uptake, which is the 
degree of swelling, was estimated at each time point using Equation 4.1: 
  
  ater uptake 
( s- i)
 p
 x 100                Equation 4.1 
 
where Ws is the weight of the swollen matrix at time, t, Wi is the initial weight of the 
matrix, and Wp is the weight of polymer in the matrix. The polymer swelling or water 
uptake data are a mean of three determinations. 
 
4.2.7 Matrix erosion studies 
Erosion studies were determined under conditions identical to those described in 
Chapter 3, Section 3.2.2.2. At pre-determined time intervals the MLMDT’s were 
removed and dried to constant weight in a hot air oven. The percentage matrix erosion 
(E) at time, t, was estimated from Equation 4.2: 
 
Matrix erosion ( )  
( i- t)
 i
 x 100                Equation 4.2 
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where Wi is the initial starting weight of the matrix and Wt is the weight of matrix 
subjected to erosion, for time, t. The matrix erosion data are a mean of three 
determinations.  
 
4.2.8 Magnetic Resonance Imaging of the MLMDT’s performance 
A magnetic resonance system with digital MARAN-iP System configured with a DRX2 
HF Spectrometer console (Oxford Instruments Magnetic Resonance, Oxon, UK) 
equipped with a compact 0.5 Tesla permanent magnet stabilized at 37oC and a 
dissolution flow through cell was employed for the viewing of the mechanical behaviors 
of the matrices. After duly configuring, optimizing the shims and probe tuning, the 
cone-like lower part of the cell was filled with glass beads to provide laminar flow at 
16mL/min of the solvents employed. The matrices were placed in position each time 
within the cell which in turn was positioned in a magnetic bore of the system and 
magnetic resonance images were acquired every 30 minutes over 13 hours with 
MARAN-iP version 1.0 software. The image was acquired after setting the frequency 
offset and testing gain employing RINMR version 5.7 under continuous solvent flow 
conditions. MARAN-iP software comprises image acquisition software and image 
analysis software. The image acquisition parameters are depicted in Table 4.6. 
 
Table 4.4: Image acquisition parameters applied during magnetic resonance imaging 
using MARAN-iP. 
Parameter Value 
Requested gain (%) 4.17 
Signal strength 68.92 
Average 2 
Matrix size 128 
Repetition time (ms) 1000.00 
Spin Echo Tau (ms) 6.80 
Image acquired after 60min 
Total scans 64 
 
4.2.9 Determination of polymeric structural variations using Fourier 
Transmission Infrared spectroscopy 
The molecular structure of the native polymers, the drug-polymer granulated blend and 
the compressed drug-loaded MLMDT were analyzed using Fourier Transmission 
Infrared spectroscopy (FTIR) (Perkin Elmer Spectrum 100 Series, Beaconfield, United 
Kingdom) to elucidate any variations in vibrational frequencies and subsequent 
polymeric structure as a result of drug-polymer or even polymer-polymer interactions. 
Changes in the polymeric backbone may affect the physicochemical and 
physicomechanical properties of the polymer and as such any changes need to be 
determined. All analyses were performed in triplicate.  
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4.2.10 Determination of deformation energy and Brinell Hardness Number 
Textural analysis was used to evaluate energy of deformation and indentation 
hardness which was converted to Brinell Hardness Number (BHN). A calibrated 
Texture Analyzer (TA.XTplus, Stable Microsystems, Surrey, England) fitted with a flat-
tipped steel probe (2mm diameter) was employed for energy of matrix deformation and 
a ball probe (2mm diameter) was utilized for indentation hardness. Hardness was 
measured as the force (N) required to indent the matrices to a set distance (mm). This 
force was then converted to BHN using Equation 4.3. Data was captured at a rate of 
200 points per second via Texture Exponent Software (Version 3.2). The employed 
settings are described in Table 4.4. All experiments were conducted in triplicate.  
 
 HN 
2F
 D(D2-d2) 
1
2⁄
                  Equation 4.3  
 
where F is the force generated from indentation, D the diameter of spherical probe 
indenter (3.175 mm), and d the indentation depth (1.563mm). 
 
Table 4.5: Textural analysis settings employed for the determination of deformation 
energy and Brinell Hardness Number.   
Parameter Settings 
Deformation Energy Brinell Hardness Number 
Pre-test speed 
Test speed 
Post-test speed 
Compression force 
Trigger Type 
Trigger Force 
Load cell 
1mm/sec 
0.5mm/sec 
10mm/sec 
40 N 
Auto 
0.05N 
5kg 
1mm/sec 
0.5mm/sec 
1mm/sec 
40 N 
Auto 
0.01N 
5kg 
 
4.2.11 Determination of surface morphology using Scanning Electron 
Microscopy  
The surface morphology of the MLMDT’s was observed using Scanning Electron 
Microscopy (SEM). Samples were mounted onto stubs and sputter coated with gold in 
a vacuum evaporator (Module™ Sputter Coater, SPI Supplies, Pennsylvania, USA) 
and then photographed using a scanning electron microscope (Phenol™ Fei 
Company, Oregan, USA). 
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4.2.12 Atomistic molecular structural mechanics simulations 
Molecular mechanics computations in vacuum, which included the model building of 
the energy-minimized structures of multi-polymer complexes, were performed using 
the HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, 
Florida, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, 
UK) (Kumar et al., 2011). The structures of EC, HEC, PEC and AVC (4 saccharide 
units each) were built from standard bond lengths and angles using sugar builder 
module on HyperChem 8.0.8. The oligosaccharide length for the polysaccharide chain 
was determined on the basis of equivalent grid surface area covered by the 
polysaccharide so that the inherent stereo-electronic factors at the interaction site can 
be perfectly optimized. The set of low-energy conformers that were in equilibrium with 
each other was identified and portrayed as lowest energy conformational model. The 
structure was built up with natural bond angles as defined in the Hyperchem software. 
The generation of the overall steric energy associated with the energy-minimized 
structures was initially executed initially via energy-minimization using MM+ force field 
and the resulting structures were again energy-minimized using the Amber 3 (Assisted 
Model Building and Energy Refinements) force field. The conformer having the lowest 
energy was used to create the polymer-polymer complexes. A complex of one 
molecule with another was assembled by disposing them in a parallel way, and the 
same procedure of energy-minimization was repeated to generate the final models: 
EC-HEC and PEC-AVC. Full geometry optimizations were carried out in vacuum 
employing the Polak–Ribiere conjugate gradient method until an RMS gradient of 
0.001kcal/moL was reached. Force field options in the AMBER (with all hydrogen 
atoms explicitly included) and MM+ (extended to incorporate non-bonded cut-offs and 
restraints) methods were the HyperChem 8.0.8 defaults. For calculations of energy 
attributes, the force fields were utilized with a distance-dependent dielectric constant 
scaled by a factor of 1. The 1-4 scale factors are following: electrostatic 0.5 and van 
der Waals 0.5. Invariant factors common to mathematical description of binding energy 
and substituent characteristics have been ignored.  
 
4.2.13 Determination of the thermal behavior of the polymeric constituents 
Thermal analysis was performed on the granulated polymers and their compressed 
versions in order to assess thermal behavior using Temperature Modulated Differential 
Scanning Calorimetry (TMDSC) (Mettler Toledo DSC1, STARe System, Switzerland). 
Thermal transitions were evaluated in terms of the glass transition temperature (Tg) 
measured as the reversible heat flow due to variation in the magnitude of the Cp-
complex values (∆Cp), melting temperature (Tm) and crystallization temperature (Tc) 
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peaks that were consequences of irreversible heat flow corresponding to the total heat 
flow. The temperature calibration was accomplished with a melting transition of 6.7mg 
indium. Samples of 7mg were weighed on perforated 40μL aluminium pans and 
ramped within a temperature gradient of 50-250°C under a constant purge of N2 in 
order to diminish oxidation. The instrument parameter settings employed comprised a 
sine segment starting at 50°C with a heating rate of 1°C/min at an amplitude of 0.8°C 
and a loop segment incremented at 0.8°C and ending at 250°C. The instrument 
parameter settings employed are described in Table 4.5. 
 
Table 4.6: Temperature modulated differential scanning calorimetry settings employed 
for thermal analysis. 
Segment Type Parameter Setting 
SINE  
Start 50°C 
Heating Rate 1°C/min 
Amplitude 0.8°C 
Period 0.8°C 
LOOP  
To segment 1 
Increment 0.8°C 
End 220a/250°C b 
Count 212a/249°C b 
a
: DTZ  
b
: THP 
 
4.3. Results and Discussion 
 
4.3.1 Assessment of the physical properties of the MLMDT’s 
The devices were uniform in mass, each having an average weight of 99.6±0.6 (Table 
4.7). The thickness ranged from 1.78±0.02 to 5.18±0.03mm while friability was 
measured at an average of 0.5±0.03% (i.e. within the set limit 1%), demonstrating 
desirable matrix compressibility.  
 
Table 4.7: Friability, thickness and mass uniformity for the DTZ and THP-loaded 
formulations (N=10). 
1 
Expressed as a percentage of the theoretical weight  
  
Formulation Friability 
(%) 
Thickness 
(mm) 
Uniformity of mass 
1(%) 
THP MLMDT 0.3 4.82±0.03 99.6±0.4 
THP lactose disk 0.9 1.78±0.02 99.4±0.6 
THP polymer disk 0.5 2.08±0.02 99.6±0.4 
DTZ MLMDT 0.3 5.18±0.03 99.7±0.3 
DTZ lactose disk 0.8 1.78±0.02 99.9±0.1 
DTZ polymer disk 0.4 2.14±0.04 99.5±0.5 
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4.3.2 In vitro drug release studies  
Based on previous preliminary studies, drug release profiles were separated into four 
phases namely, the lag-phase, the first pulse of drug release, the ―switch-off‖ phase 
and second pulse of drug release. Consequently, the rate release constant (k) for each 
phase was calculated based on the power law expression (Equation 4.4) describing 
drug release from simple swellable matrix systems. 
  
Mt M ⁄  k1t
n
                  Equation 4.4 
 
where Mt/M   is the fraction of drug released at time t, k is the release rate constant 
and n is the release rate exponent.  
 
The rate constant pertaining to the initial lag-phase, first phase of drug release, 
―switch-off‖ phase and second phase of drug release were termed k1, k2, k3 and k4 
respectively. Ideally k3 should be 0. Table 4.8 highlights the rate constants of the 21 
chosen formulations.  
 
Table 4.8: The rate constants of the various formulations.  
Formulation k1 
(lag phase) 
k2 
(first pulse) 
k3 
(switch-off 
phase) 
k4 
(second pulse) 
1 0.031 0.089 0.042 0.026 
2 0.034 0.069 0.040 0.026 
3 0.018 0.049 0.034 0.015 
4 0.038 0.092 0.049 0.020 
5 0.018 0.040 0.039 0.028 
6 0.056 0.071 0.048 0.033 
7 0.018 0.047 0.034 0.026 
8 0.022 0.045 0.031 0.020 
9 0.018 0.053 0.036 0.029 
10 0.021 0.044 0.034 0.030 
11 0.024 0.051 0.029 0.031 
12 0.048 0.075 0.049 0.021 
13 0.042 0.062 0.051 0.030 
14 0.017 0.12 0.063 0.029 
15 0.021 0.095 0.032 0.025 
16 0.019 0.092 0.025 0.032 
17 0.013 0.062 0.021 0.027 
18 0.027 0.055 0.034 0.020 
19 0.010 0.067 0.035 0.022 
20 0.038 0.010 0.057 0.036 
21 0.019 0.090 0.042 0.021 
 
Drug release profiles indicate that the formulations displayed an initial lag phase 
(Figure 4.2 and 4.3) due to the barrier layers surrounding the disks. Thereafter, a rapid 
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increase in drug release was observed which is attributed to erosion of L1 and the 
subsequent exposure of the D1 to the media. After complete release of drug from D1, 
drug release from all formulations decreased and then gradually increased. The 
release of drug from D2 is controlled by the barrier layers and the type of polymer 
utilized. Due to the highly hydrophobic nature of EC, formulations containing pure EC 
(F3, F4, F5, F6 and F12) displayed poor drug release (<50%) over the 24-hour period 
(Figure 4.2a, b and Figure 4.3a). Formulations that employed hydrophilic polymers (F1, 
F2, F7 and F9) demonstrated higher rates of drug release although instead of a 
―switch-off‖ phase, biphasic release was observed (Figure 4.2a and c). Utilizing both 
hydrophobic and hydrophilic polymers (F10-F21) gave rise to an overall increase in the 
rate of drug release as compared to utilizing hydrophobic polymers on their own.  
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Figure 4.2: Release profiles depicting THP-loaded MLMDT’s: a) formulation 1 to 4; b) 
formulation 5 to 8 and c) formulation 9 to 11 10 (N=3; SD <0.22 in all cases).  
c) 
b) 
a) 
58 
 
4.3.3 The effect of sodium bicarbonate on drug release from DTZ-loaded 
MLMDT’s 
DTZ is known for its high water solubility (>50% at 25°C) making controlled release a 
challenge. This is demonstrated in Formulation 12 (Figure 4.3a and b) where DTZ is 
combined with the EC. Despite the hydrophobic nature of EC, release occurs 
simultaneously from both disks resulting in biphasic release. To counteract this 
problem the electrolyte sodium bicarbonate was incorporated into the formulation. 
Sodium bicarbonate is known to control the release rate of DTZ as demonstrated by 
Pillay and Fassihi (1999). Sodium bicarbonate was utilized in varying quantities in D2, 
L2 and L3 (Table 4.3) in Formulations 14, 15, 16, 17, 18, 19 and 21. Drug release 
analysis from these formulation demonstrate that the rate of drug release is 
considerably lower (Figure 4.3) than formulations without sodium bicarbonate.  
 
Based on the drug release profiles sodium bicarbonate should ideally be placed in D2, 
L2 and L3 to produce the ―switch-off‖ phase. Furthermore, utilizing high concentrations 
(more than 150mg) of sodium bicarbonate per formulation reduced drug release 
significantly resulting in incomplete drug release after the 24 hour period (F17 and 
F18). Formulations that served as controls i.e. had no sodium bicarbonate (F12, F13 
and F20) displayed biphasic release instead of two pulse release further substantiating 
the ―matrix-stiffening‖ effect of sodium bicarbonate.  
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Figure 4.3: Typical release profiles illustrating drug release from DTZ-loaded 
MLMDT’s a) formulation 12 to 14; b) formulation 15 to 17 and c) formulation 18 to 21 
(N=3; SD <0.35 in all cases). 
c) 
b) 
a) 
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4.3.4 Employment of an ANN approach to generate an optimized formulation for 
both THP and DTZ-loaded MLMDT’s 
Results obtained from the ANN model including the average of the mean square error 
(MSE) (Figure 4.4) values for all the training runs and the best network run out of 
10,000 epochs are highlighted in Table 4.9 and 4.10 respectively. The correlation 
coefficient of R2=0.98 (Table 4.11) determined from the comparison between the 
desired output and actual output of k3 (Figure 4.5) suggests that the training model 
utilized was extremely efficient.  
 
Figure 4.4: Average mean square error (MSE) with standard deviation (SD) 
boundaries for 10,000 epochs. 
 
 
 
Table 4.9: Results obtained from ANN modeling. 
All Runs Training Minimum Training Standard 
Deviation 
Average of Minimum MSEs 0.016 0.0059 
Average of Final MSEs 0.016 0.0059 
 
 
 
Table 4.10: Table depicting best network run. 
Best Network  Training 
Run # 2 
Epoch # 1000 
Minimum MSE 0.0098 
Final MSE 0.098 
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Table 4.11: Table depicting optimized ANN parameters. 
Performance K3 
MSE 4.51E-06 
NMSE 0.056 
MAE 0.0015 
Min Abs Error 0.00011 
Max Abs Error 0.0053 
Correlation coefficient R
2
 0.98 
MSE: Mean square error 
NMSE: Normalized mean square error 
MAE: Mean absolute error 
Min Abs Error: Minimum absolute error 
Max Abs Error: Maximum absolute error 
 
 
 
 
Figure 4.5: A diagrammatic profile depicting the desired and actual network output. 
 
Results from sensitivity testing suggest that the quantity of HEC in D2 has the greatest 
influence on the shape of the drug release profiles (Figure 4.6). This is substantiated in 
Figure 4.7(a) which demonstrates a linear curve for HEC, suggesting that the 
concentration of HEC greatly affects the drug release while increasing the 
concentration of EC has a minor effect on the rate of drug release.  
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Figure 4.6: A typical bar chart portraying the sensitivity of HEC, EC and sodium 
bicarbonate on k3. 
 
 
Figure 4.7: Graphical profile depicting the correlation between the polymers on k3. 
 
The compositions and quantities of the optimized formulation as determined by the 
ANN approach are depicted in Table 4.12, while drug release profiles are depicted in 
Figure 4.8. All further experiments were carried out on the optimized THP-loaded and 
DTZ-loaded formulations.  
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Table 4.12: Combination of polymers to produce the optimum k3. 
    Sodium Bicarbonate 
Drug Polymer  Polymer Ratio D2 L1
 
L2 
THP HEC EC 1:3 - - - 
DTZ HEC EC 1:1 50 50 50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Drug release profiles of optimized THP and DTZ-loaded MLMDT’s (N=3; 
SD <0.21 in all cases). 
 
4.3.5 Matrix swelling and erosion analysis 
Swelling and erosional studies were performed on the optimized formulations. Figure 
4.9a and b, depicts the relationship between swelling and erosion on THP and DTZ-
loaded MLMDT’s. The THP-loaded formulation expanded to 80% of the original size 
within the first two hours with less than 10% of the device displaying erosion. This 
initial swelling contributes to the initial lag phase observed in the drug release profiles 
(Figure 4.8). After 2 hours a sharp decrease in the % water intake (i.e. swelling) was 
observed as erosion of L1 and D1 commenced. At the same time swelling from the 
exposed areas of L2 commenced. Between 6 and 8 hours swelling and erosion of the 
device remained constant (Figure 4.10d and e) and by 6 hours erosion of L1 and D2 
was complete. After 24 hours a slight decrease in swelling was observed while erosion 
increased to 60%. The MLMDT was intact after 24 hours which explained the 
incomplete drug release detected (Figure 4.10g).  
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Figure 4.9: Correlation of swelling and erosion profiles of: a) THP-loaded and b) DTZ-
loaded MLMDT’s (N=3; SD <0.52 in all cases). 
  
 
 
a) 
b) 
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Figure 4.10: Digital images illustrating THP-loaded MLMDT’s at: a) 2; b) 4; c) 6; d) 8; 
e) 10; f) 12 and g) 24 hours. 
 
The addition of an alkaline compound to an acidic drug resulted in a buffering effect 
which consequently inhibited the release of drug (Pillay and Fassihi, 1999). An 
increase in swelling was observed within the first two hours contributing to the initial lag 
phase. Thereafter, there was a drop in the swelling percentage similar to the THP-
loaded MLMDT’s due to the erosion of L1 and D2.  
 
The DTZ formulation expanded more than 100% in the first 2 hours followed by a 
constant increase in the swelling as well as the erosion over the next 10 hours (Figure 
4.9 and 4.11). Despite an increase in swelling, minimal drug was released between 4 
hours and 11 hours confirming that sodium bicarbonate influenced the rate of drug 
release. After 12 hours a sharp decrease in swelling was observed which corresponds 
to an increase in drug release. Figure 4.11f depicts the swollen matrix with D2 visible. 
After 24 hours approximately 20% of the device remained (Figure 4.11g) indicating that 
the majority of drug was released. 
  
a) b) c) d) 
e) f) g) 
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Figure 4.11: Digital images illustrating DTZ-loaded MLMDT’s at: a) 2; b) 4; c) 6; d) 8; 
e) 10; f) 12 and g) 24 hours. 
 
4.3.6 Magnetic Resonance Imaging of MLMDT’s performance 
Magnetic Resonance Imaging (MRI) covers a range of widely used techniques for 
studying the distribution and dynamics of a species within a material based on their 
nuclear magnetic resonance effects (Richardson et al., 2005; Laity et al., 2010). This 
technique proves to be a powerful tool for following the progression of hydration over a 
period of time (Mikac et al., 2010). MRI was therefore employed to observe and 
confirm our postulation for the chronotherapeutic behaviors and performance of the 
MLMDT’s during dissolution studies. Figure 4.12 exhibits the images obtained for the 
THP-loaded MLMDT’s under continuous solvent flow conditions while Figure 4.14 
displays the images obtained for DTZ-loaded MLMDT’s throughout the image 
acquisition process under continuous solvent flow conditions. The images displayed 
were obtained after every thirty minutes. The grey area surrounding the matrix 
indicates the dissolution medium (simulated gastrointestinal fluid). The black area 
within the matrix represents the non-hydrated and non-gelled area of the device. As 
the matrix hydrated, it swelled and gelled which is represented by the white area were 
the thickness increased over time until the matrix was fully hydrated and gelled.  
 
The layers surrounding the device gelled on exposure to the dissolution media with L1 
gelling faster than L2 and L3 (Figure 4.12a-aa). As the device gelled, no drug release 
b) a) c) d) 
e) f) g) 
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was observed. After 2.5 hours media penetrated the device (Figure 4.13) hydrating the 
inner layers (4.12f and 4.12g). Based on dissolution data (Figure 4.13) complete drug 
release from D1 occurred after 3 hours while complete erosion of D1 occurred after 6 
hours (4.12m). This observation indicated that the gel at the layer interface was not 
tight or viscous enough to retard drug release which resulted in drug movement from 
D1 across the swollen outer layer (L1) into the dissolution media. D2 was protected 
from the surrounding media due to the highly viscous HPMC contained in L2 and L3 
that prevented buffer penetration at the layer-disk interface. D2 was fully visible after 
11 hours due to the ingress of buffer into the device. Drug release from D2 occurred 
thereafter due to the decrease in the viscosity of the surrounding gel after 12 hours 
(4.12t), thus facilitating drug movement from the core into the media. 
 
      
(a) 0hr   (b) 0.5hr  (c) 1hr   (d) 1.5hr 
     
(e) 2hr   (f) 2.5hr  (g) 3hr   (h) 3.5hr 
     
(i) 4hr   (j) 4.5hr  (k) 5hr  (l) 5.5hr 
 
     
(m) 6hr  (n) 6.5hr  (o) 7hr   (p) 7.5hr 
Figure 4.12: MRI depicting the progression of hydration of THP-loaded MLMDT’s from 
0 to 7.5 hours. 
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(q) 8hr   (r) 8.5hr  (s) 9hr   (t) 9.5hr 
     
(u) 10hr   (v) 10.5hr  (w) 11hr (x) 11.5hr 
   
(y) 12hr   (z) 12.5hr 
 
Figure 4.12 (continued): MRI depicting the progression of hydration of THP-MLMDT’s 
from 8 to 13 hours. 
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Figure 4.13: Drug release profile detailing the relationship between drug release and 
the results obtained using MRI from THP-loaded MLMDT’s with P1, P2, P3 and P4 
representing the lag phase, first pulse of drug release, ―switch-off‖ phase and second 
phase of drug release respectively. 
 
The DTZ-loaded formulation generated CO2 due to the inclusion of sodium bicarbonate 
in the device. This liberation of CO2 resulted in floatation of the device (4.14a-4.14v). 
L1 swelled more than the other layers upon contact with the media (4.14b). Penetration 
of buffer into the device happened after 1 hour (4.14c and d). Disintegration of the PEC 
layer (L1) occurred after 3.5 hours (4.14d) with complete hydration of L2 and L3 
occurring after 8 hours (4.14l). Although the matrix around D2 was hydrated no drug 
release occurred due to a ―matrix-stiffening‖ effect generated by sodium bicarbonate 
resulting in a ―switch-off‖ phase (Figure 4.15). This effect diminished after 11 hours 
(4.14r) and drug release commenced for the remainder of the 24 hours.   
 
 
P1 P2 P3 P4 
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(a) 0hr   (b) 1hr   (c) 1.5hr                     (d) 2hr 
 
(e) 2.5hr  (f) 3hr   (g) 4hr   (h) 5hr 
 
(i) 6hr   (j) 7hr   (k) 7.5hr  (l) 8hr 
  
(m) 8.5hr  (n) 9hr   (o) 9.5hr  (p) 10hr 
 
(q) 10.5hr  (r) 11hr  (s) 11.5hr  (t) 12hr 
  
(u) 12.5hr   
 
Figure 4.14: MRI depicting the progression of hydration over time from DTZ-loaded 
MLMDT’s. 
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Figure 4.15: Profile portraying the association between drug release and images 
obtained by MRI from DTZ-loaded MLMDT’s with P1, P2, P3 and P4 representing the 
lag phase, first pulse of drug release, ―switch-off‖ phase and second phase of drug 
release respectively. 
 
4.3.7 Analysis of the polymeric structural variations using Fourier Transmission 
Infrared spectroscopy  
Fourier Transmission Infrared spectroscopy (FTIR) was carried out on the native 
polymer and drug as well as the granulated forms (not shown) and compressed forms 
of the formulation. The spectra were then compared to determine if there were 
changes in any of the structures. FTIR spectra of both the compressed THP 
formulation (Figure 4.16a) and the compressed DTZ formulation (Figure 4.16b) 
displayed no change in the structure of the compressed final MLMDT in comparison 
with the native polymer and drug. Both figures illustrated the characteristic cellulose 
bands arising at 3476cm-1 and 2934cm-1 indicative of EC, HPMC and HEC. Figure 
4.16a demonstrates the native THP peaks which were observed at 785cm-1, 1585cm-1, 
1715cm-1 and 2509cm-1. This indicates the drug remained unchanged during 
compression. Similarly Figure 4.16b highlights the characteristic DTZ bands observed 
at 1680cm-1, 1741cm-1 and 2363cm-1 indicative of the stretching of the carbonyl in the 
amide group, which was present in the compressed MLMDT. Therefore, the observed 
spectrum could be regarded as a simple superimposition between the native polymers 
and drug, suggesting that no interaction occurred between the polymer and the drug.  
 
 
 
P1 P2 P3 P4 
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                                           Figure 4.16: FTIR spectra depicting pure THP and compressed THP-loaded MLMDT.   
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                                                  Figure 4.17: FTIR spectra depicting pure DTZ and compressed DTZ-loaded MLMDT. 
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4.3.8 Determination of deformation energy and Brinell Hardness Number 
The MLMDT’s comprised different polymers on the top and bottom layers (Figure 4.17) 
and thus hardness was determined on both the top and bottom layers of the MLMDT. 
Results show that L3 was considerably harder than L1 (Table 4.13).  
 
 
Figure 4.18: A digital image of the MLMDT illustrating the variation between the 
bottom and top layers of the device as based on the different polymers utilized in the 
layers.  
 
 
Table 4.13: Brinell Hardness Numbers values for the MLMDT’s. 
Formulation BHN (N/mm2)  
THP MLMDT Layer one 5.35 
THP MLMDT Layer three 6.49 
DTZ MLMDT Layer one 5.27 
DTZ MLMDT Layer three 6.60 
 
Textural analysis was also employed to measure alterations in swelling behavior. 
Force-displacement profiles for optimized DTZ and THP-loaded formulations were 
obtained using the Texture Exponent Software (version 2). Figure 4.18a illustrates the 
force-displacement placement profiles for THP-loaded formulations, while Figure 4.18b 
displays the profile for DTZ-loaded formulations. The upward curving of the graph 
suggests the force required to penetrate the swollen matrix, with a smaller force 
needed to penetrate the gel layer. This force increases once the probe penetrates the 
dry core. The rapid decline in the curves indicates the retraction of the probe from the 
swollen matrix (Figure 4.18a and b). THP-loaded formulations expanded significantly 
within the first two hours followed by a decline in size of the device. This corresponds 
to the erosion of L1. Swelling progressively increased with the final measurement at 24 
hours demonstrating a decline in the overall size. These sequential events coincide 
with the data obtained from % water uptake (swelling) studies. DTZ-loaded 
formulations displayed a considerable increase in swelling up to 10 hours and then a 
decline in swelling as erosion increases. Swelling was greater in the DTZ-loaded 
formulation compared to the THP-loaded MLMDT. This was attributed to the inclusion 
of sodium bicarbonate in the DTZ-loaded formulations.  
PEC/AVC® (L1)
HPMC (L2 and L3)
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Figure 4.19: Typical force-displacement profiles for: a) THP-loaded MLMDT’s and b) 
DTZ-loaded MLMDT’s. 
 
4.3.9 Evaluation of Scanning Electron Microscopy (SEM) imaging 
SEM was conducted on the compressed MLMDT to observe the surface morphology of 
the different layers. As highlighted in Figure 4.19, there is a distinct difference in the 
surface structure of the L1 and L2. This variation in structure accounts for the different 
rates of erosion and swelling and consequently the drug release kinetics. 
a) 
b) 
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Figure 4.20: SEM image of the side view of the MLMDT illustrating morphology the of 
the PEC/AVC and HPMC layer (magnification 355x). 
 
4.3.10 Molecular mechanics assisted model building and energy refinements 
A molecular mechanics conformational searching procedure was employed to acquire 
the data employed in the statistical mechanics analysis, to obtain differential binding 
energies of a Polak–Ribiere algorithm and to potentially permit application to EC-HEC 
and PEC-AVC polymer composite assemblies. MM+ is a HyperChem modification and 
extension of Norman Allinger's Molecular Mechanics program MM2 (Warhurst et al., 
2003) whereas AMBER, is a package of computer programs for applying molecular 
mechanics, normal mode analysis, molecular dynamics and free energy calculations to 
simulate the structural and energetic properties of molecules (Pearlman et al., 1995).  
 
4.3.10.1 Molecular mechanics energy relationship analysis 
Molecular mechanics energy relationship (MMER), a method for analytico-
mathematical representation of potential energy surfaces, was used to provide 
information about the contributions of valence terms, noncovalent Coulombic terms, 
and noncovalent van der Waals interactions for the blended-polysaccharide 
morphologies and interactions. The MMER model for the potential/steric energy factors 
in various molecular complexes can be written as: 
  
PEC/AVC 
® (L1) 
HPMC (L2 and L3) 
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Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel  ...     Equation 4.5 
EEC = 72.116V∑ = 3.551Vb + 32.878Vθ + 26.457Vφ+ 8.746Vij - 0.209Vhb+ 0.691Vel   Equation 4.6 
EHEC=130.862V∑= 4.017Vb+ 35.115Vθ+ 80.816Vφ+ 10.28Vij - 0.231Vhb + 0.863Vel   Equation 4.7 
EEC/HEC = 115.616V∑ = 7.861Vb + 72.277Vθ + 44.159Vφ + 10.968Vij - 2.578Vhb - 17.072Vel  Equation 4.8 
[ΔEBINDING = -87.362kcal/mol] 
EPEC=-25.743V∑ =2.030Vb+ 16.827Vθ + 26.87Vφ + 7.085Vij - 3.399Vhb - 75.157Vel   Equation 4.9 
EAVC = -4.641V∑ = 1.477Vb + 8.718Vθ + 6.145Vφ + 13.110Vij - 34.094Vel   Equation 4.10 
EPEC/AVC = -65.913V∑ = 3.824Vb + 28.882Vθ + 40.252Vφ + 7.804Vij - 4.933Vhb - 141.745Vel  Equation 4.11 
[ΔEBINDING = -35.529kcal/mol] 
 
where, V∑ is related to total steric energy for an optimized structure, Vb corresponds to 
bond stretching contributions (reference values were assigned to all of a structure's 
bond lengths), Vθ denotes bond angle contributions (reference values were assigned to 
all of a structure's bond angles), Vφ represents torsional contribution arising from 
deviations from optimum dihedral angles, Vij incorporates
 van der Waals interactions 
due to non-bonded interatomic distances, Vhb symbolizes hydrogen-bond energy 
function and Vel stands for electrostatic energy. 
 
4.3.10.2 Energy-minimizations involving composite polysaccharide 
morphologies 
The energy minimized structures of the EC-HEC and PEC-AVC following molecular 
mechanics simulations are depicted in Figure 4.20 and 4.21 and the possible 
component binding energies to which they will be responsive, are listed in Equations. 
4.9-4.11. Molecular modelling studies can account for specific interactions between 
polymer segments and may provide an estimate of whether two polymers will form a 
compatible blend. Our theoretical foundation for this method relies upon the 
thermodynamic factors dominated by the energetics of local interactions between 
segments of the polymer chains involved in modelling computations (Tiller and Gorella, 
1994).   
 
It is evident from the energy value that the EC-HEC complex (representing base disc) 
is stabilized by a binding energy of ~87kcal/moL (ΔEBINDING = -87.362kcal/mol; 
Equations. 4.6-4.8). On a theoretical basis, a necessary condition for the miscibility of a 
mixture of two polymers is a negative free energy of mixing (Tiller and Gorella, 1994). 
This energy minimization in case of EC-HEC was inherent from rotation of 
monosaccharide residues producing strain due to steric interactions which in turn are 
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relieved by the inclusion of bond length and angle adjustment with respect to all 
degrees of freedom of the system. As obvious from comparison between Figure 4.18a  
and b, a lowering of the energy barriers caused a substantial change from the initial 
starting geometry. The pendent groups (ethyl and hydroxyl ethyl) moved to their 
nearest minimum downhill of the starting point during minimization, driving the 
molecule through unfavourable regions. These large steric interactions cause pendent 
groups to overcome torsional barriers presenting a larger accessible potential energy 
surface (Perez et al., 1996). This torsional energy stabilization (ΔEVφ~62kcal/mol) 
contributed mainly to the finally stabilized geometrical configurations. These energy 
optimizations are also supported by high magnitude van der  aals interactions (ΔEVel 
~20kcal/moL) between the two 4-saccharide unit’s sugar molecules. Furthermore, 
regarding the spatial preference of EC with HEC, as depicted by the dots rendering in 
Figure 4.18b, a deeper inspection revealed the close proximity of both the molecules in 
form of H-bonding and closely sharing the van der Waals space. These underlying 
weak chemical interactions may not cause a structural change in the polymers but may 
initiate aggregation of the aliphatic chains, as both the polymers here contain aliphatic 
side chains, creating localized regions with a density and refractive index different from 
that of the bulk polymers. Additionally, the hydroxyl group induced inter- and 
intramolecular hydrogen bonding in EC-HEC (≈10 times more than the individual 
polymers) (Figure 4.20b) may influence the hydration process of the EC polymer matrix 
causing a ―notable increase in the amount of drug released over a given period‖ as 
explained earlier in the manuscript. This release pattern may be attributed to the 
modified matrix hydration process of EC (hydrogen bonding induced by the presence 
of the HEC) and continued retarded release of drug due to the entanglement of 
saccharide chains which in turn lead to a high BHN of L3 as highlighted in Table 4.13. 
 
Similarly, the molecular mechanistically minimized energy value for PEC-AVC complex 
(representing L1) is stabilized by a binding energy of ~35kcal/moL (ΔEBINDING = -
35.529kcal/mol; Equations. 4.9-4.11). Molecular modelling proved to be a powerful tool 
for studying the packing of polysaccharides where the models can be built and 
energies involving chain-chain interactions can be calculated as described by Perez et 
al, 1996. Here also in case of PEC-AVC, the PEC’s interaction with cellulose is 
calculated at varied helix axis translations and mutual rotational orientations while 
keeping the helices in van der Waals contact (Figure 4.21a and b). For efficient 
packing, coupled values of the rotations of the individual chains are also important 
along with low energy of stabilization. These very rotations caused the formation of 
bonding interactions in form of torsional energy minimization (~10kcal/mol), formation 
79 
 
of H-bonds (~12kcal/mol) and highly stabilized electrostatic interactions (~30kcal/mol) 
leading to the formation of a rotation axis might even be a screw axis (Figure 4.20a 
and b). These interactions involving the non-bonded attractive forces may induce 
dipoles in the complex where the binding energy changes should be proportional to the 
polarizability of the substituent’s, which are in turn may lead to the formation of a dense 
polymer network responsible for prolonged release of the bioactives (Figure 4.20).  
 
The higher energy of stabilization (ΔEBINDING) of EC-HEC as compared to PEC-AVC 
corroborated with the chronotherapeutic strategy explained in this research. PEC-AVC 
being less stabilized molecular complex is supposed to erode faster than EC-HEC 
leading to the release of drug from L1 earlier than that from base disc. Hence, the 
present modeling and computation method involving four polysaccharides provided a 
justification of using a definite combination of polymers to meet the requirements of a 
drug delivery system with the desired release profile. This delivery system and 
subsequent modeling system may act as a template for the future applications 
employing various drug and polymer combination strategies involving 
chronotherapeutic and desired release profile requirements. 
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Figure 4.21: Energy minimized geometrically constrained models of: a) ethylcellulose 
and hydroxyethyl cellulose before complexation; and b) EC-HEC complex derived from 
molecular mechanics calculations. The atoms in close interaction proximity are 
emphasized by space filling model (dots) where the yellow dots depict atoms involved 
in H-bonding. Color codes for elements are: Carbon (cyan), Nitrogen (blue) and 
Oxygen (red) and Hydrogen (white). 
a) 
b) 
EC 
HEC 
HEC 
 
EC 
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Figure 4.22: Energy minimized geometrically constrained models of a) AVC (cellulose) 
and PEC before complexation; and b) PEC-AVC complex derived from molecular 
mechanics calculations. The atoms in close interaction proximity are emphasized by 
space filling model (dots) where the yellow dots depict atoms involved in H-bonding. 
Color codes for elements are: Carbon (cyan), Nitrogen (blue) and Oxygen (red) and 
Hydrogen (white). 
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4.3.11. Determination of the thermal behavior of the polymeric constituents 
DSC analysis of both the polymer blend and the granules revealed a Tc of 130°C 
indicating the presence of EC (Figure 4.22). Further thermal events are obscured and 
thus TMDSC analysis was employed. TMDSC provides additional information about 
time-dependent processes in the sample. TMDSC has the ability to separate reversible 
glass transition temperatures from overlapping non-reversible relaxation endotherms 
(Höhne, 1999). TMDSC analysis was conducted on the granules and polymer blend. 
Figure 4.22a and b illustrates the reversible, non-reversible and total heat flow of THP 
and DTZ polymer blend and the granules. The Tg of HEC is present at 72°C and 95°C 
for EC. Based on the information presented in these thermoanalytical curves it may be 
concluded that no significant interactions are presented. Results obtained from studies 
of DTZ polymer blends further confirm the results obtained with THP indicating that the 
drug has no influence on the thermal behavior of the device. This corresponds with 
results obtained from FTIR analyses.  
 
 
 
 
Figure 4.23: Thermogram of a) THP granules and b) DTZ granules depicting the 
endothermic and exothermic peaks generated.  
b) 
a) 
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4.4 Concluding Remarks 
The optimized MLMDT was successfully developed. The system comprised two drug-
loaded disks enveloped by barrier layers. The optimized formulations included 
PEC/AVS utilized in L1 and HPMC utilized in L2 and L3. D1 comprised lactose and D2 
comprised HEC and EC. DTZ-loaded formulations also comprise of sodium 
bicarbonate in D1, L2 and L3. Friability, hardness and uniformity of mass were all 
within the specified limits depicting desirable manufacturing settings. The developed 
drug delivery system displays the desired release profile with two pulses of drug 
release, separated by a ―switch-off‖ phase. The ―switch-off‖ phase is dependent on the 
polymers utilized in the polymer disk, with the concentration of HEC and sodium 
bicarbonate being the most important factors in producing the ―switch-off‖ phase. MRI 
results confirmed the data obtained from drug release and swelling and erosion 
studies. Furthermore, results from DSC highlighted no interaction between the 
polymers and drug and between the polymers themselves. The experimental results 
were well corroborated by the Molecular Mechanics Computations. Overall, the 
MLMDT is an innovative drug delivery system that displays potential as a 
chronotherapeutic drug delivery system. 
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CHAPTER FIVE 
IN VIVO ANALYSES ON THE OPTIMIZED MULTI-LAYERED MULTI-DISK TABLET 
IN THE LARGE WHITE PIG MODEL 
 
 
5.1 Introduction 
 
A crucial step in the formulation of a new drug delivery system is conducting in vivo 
animal studies. Data generated can be used to assess safety and efficacy of a dosage 
form and more importantly to predict the pharmacokinetics and pharmacodynamics of 
the system in humans. Over the years studies were conducted in a variety of animal 
models. These include rats (Miyazaki et al., 1999; Tarvainen et al., 2000, Blanco et al., 
2003; Nagahara et al., 2007; Pillay et al., 2009), rabbits (Ugwoke et al., 1999; Latha et 
al., 2000; Fernandes et al., 2003; Choonara et al., 2006; Ndesendo et al., 2009), dogs 
(Ishibashi et al., 1999; Löbenberg et al., 2005; Gao et al., 2006; Ghimire et al., 2007; 
Lavy et al., 2010) and monkeys (Haddish-Berhane et al., 2006).  
 
Though similarities do exist between the gastrointestinal tract (GIT) of animals and 
humans, no single animal model completely resembles the GIT of humans. The 
differences between the anatomy and physiology of the GIT explain the variation in the 
pharmacokinetics and pharmacodynamics of a compound between human and 
animals (Hildebrand et al., 1991; Dali et al., 2006). Selection of an appropriate animal 
model largely depends on the dosage form and frequency of administration 
(Hildebrand et al., 1991). Due to the size of the oral dosage forms and the numerous 
samples needed, rodents and rabbits are excluded. Dogs, pigs and monkeys are 
suitable due to similarities in the anatomy of the stomach to humans though the use of 
dogs and monkeys has been limited due to their restricted availability, high cost and 
the social pressure of special interest groups. In addition, the size of dogs limits their 
use as the volume of blood that can be removed is restricted (Kostewicz et al., 1996). 
 
The pig (Sus scrofa domestics) has gained popularity as an animal model in 
biomedical research due to the anatomical resemblance shared with humans. They are 
large animals enabling multiple blood sampling and share similarities in metabolism, 
biotransformation (cytochrome P450), feeding patterns dietary habits, kidney function 
and structure, pulmonary vascular bed structure and respiratory rates (Brunet et al., 
2006). 
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In the previous chapter various formulations were analyzed to determine in vitro drug 
release. The formulations were subjected to optimization using ANN and one optimized 
formulation for each drug was generated. This chapter deals with in vitro comparative 
studies between the optimized formulations and a conventional system currently on the 
market as well as in vivo testing of these formulations using the large white pig as an 
animal model.   
 
5.2 Animal Ethics 
This study had received the approval from the Animal Ethics Screening Committee of 
the University of the Witwatersrand with ethics clearance number 2007/56/04. 
(Appendix E). 
 
5.3 Materials and Methods 
 
5.3.1 Materials 
Materials utilized in the tablet making process were the same as in Chapter 3, Section 
3.2.1. Methylparaben (MP) (Merck (Pty) Ltd., Darmstadt, Germany) was utilized as an 
internal standard. Ketamine (Bayer (Pty) Ltd, Isando, South Africa), midazolam (Roche 
Products (Pty) Ltd, Isando, South Africa), Buprenorphine (Schering-Plough, Rio de 
Janeiro, Brazil), Carprofen (Pfizer Ltd, Kent, UK), heparin (1000IU/mL), saline (Bodene 
(Pty) Ltd., Port Elizabeth, South Africa) and isoflurane (Safeline Pharmaceuticals (Pty) 
Ltd. Johannesburg, South Africa) were employed during the surgical procedure. 
Double deionized water was obtained from a Milli-Q system (Milli-Q Millipore, 
Massachusetts, USA), while analytical grade acetonitrile and methanol (Rompil-Sp-
S™, Cambridge, UK) comprised the mobile phase solvents. All other reagents used 
were of analytical grade. Theoplus® CR 200 (Altana Madaus, Johannesburg, South 
Africa) and Zildem CR 180 (Adcock-Ingram, Johannesburg, South Africa), were 
employed as comparator products. 
 
5.3.2 Preparation of the MLMDT device 
The MLMDT’s were prepared according to the method described in Chapter 3, Section 
3.2.2.1. A digital image illustrating the disk and the layers of the MLMDT is depicted in 
Figure 5.1. 
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Figure 5.1: Digital photographs of a) the drug loaded disk, b) the fully compressed 
MLMDT and c) a cross section depicting the various layers. 
 
5.3.3 In vitro drug release analysis of the optimized MLMDT and comparator 
systems 
Drug release from Theoplus® CR 200 and Tilazem® CR 180 were compared to that of 
the optimized THP and DTZ-loaded MLMDT’s using USP dissolution apparatus II as 
described in Chapter 3, Section 3.2.2.4. 
 
5.3.4 In vivo animal studies 
 
5.3.4.1 Procurement and pre-surgical preparation of pigs 
Five large white female pigs ranging in weight from 30-35kg were sourced from Animal 
Nutrition and Products Institute of the Agricultural Research Council (Pretoria, South 
Africa). The animals were housed in standard animal rooms at the Central Animal 
Service Unit at the University of the Witwatersrand (Johannesburg, South Africa) with 
access to food and water. Habituation began 7 days pre-surgery through feeding and 
repeated visits. Habituation and domestication allowed the pigs to adapt to contact and 
handling by humans (Figure 5.2).  
  
 
 
a)    b)   c)  
L1 
D1 
L3 
D2 
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Figure 5.2: Habituation and domestication of the pigs utilized in the study at the 
Central Animal Service Unit. 
 
5.3.4.2 Insertion of a chronic catheter for blood sampling 
The pigs were anaesthetized with ketamine (11mg/kg I.M.) and midazolam (0.3mg/kg 
I.M.). Buprenorphine (0.05mg/kg I.M.) and carpofen (4mg/kg I.M.) were administered 
for analgesia and inflammation. The pig was then intubated and anesthesia was 
maintained with 2% isoflurane in 100% oxygen. Under aseptic conditions, a 7 French 
gauge double lumen 35cm catheter (CS-28702) (Arrow Deutschland GmdH, Erding, 
Germany) was surgically inserted into the left jugular vein. The jugular vein was 
exposed by an incision made dorsal to the jugular groove on the left lateral aspect of 
the neck. Via blunt dissection, the vein was isolated and the catheter was inserted 
10cm into the lumen of the vein. The lumen of the catheter was fastened to the wall of 
the vein using a purse suture technique. The remaining length of the catheter (25cm) 
was tunneled subcutaneously, with the use of a trocar, to an exit point cranial to the 
dorsal aspect of the scapular. The externalized injection ports of the catheter were 
sutured to the skin of the pig so as to limit excessive movement and bending. The 
surgical process is depicted in Figure 5.3. Blood was removed via the catheter and the 
catheter was flushed with heparin saline (1000 i.u. of heparin in 1L of 0.9% saline). 
Thereafter, the animal was allowed 10 days to recover from the surgical procedure. 
During this time it was further habituated to the process of blood sampling. Throughout 
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the study, the catheter was flushed with heparinized saline three times a day to prevent 
blockage.   
 
 
Figure 5.3: Digital photographs depicting: a) sedation and preparation for surgery, b) 
administration of anesthesia, c) incision into the jugular area permitting the 
confinement of the jugular vein, d) insertion of the catheter into the jugular vein, e) 
external ports sutured to the skin of the pig and f) recovery. 
 
5.3.4.3 Oral administration of the MLMDT and conventional systems 
Administration of the dosage forms were executed in 5 pigs at a time, dosed on 
separate occasions with an appropriate wash-out period separating each dosing. The 
dosage administration was separated into 6 groups (Figure 5.4). Dosing of the pigs 
commenced 10 days post-surgery allowing the animals to fully recover. Animals were 
fasted for 12 hours prior to administration with access to water only. Prior to dosing the 
jugular catheters were flushed with heparinized saline followed by blood sampling to 
acquire a baseline sample. The pigs were sedated with intramuscular midazolam 
(0.3mg/kg) and anesthetized with ketamine (4mg/kg). The animal was maintained 
under anesthesia by gaseous administration of 2% isoflurane in 100% oxygen via a 
face mark. The animal was then placed in an upright position and intubated with a bore 
gastric tube (Figure 5.5) through the esophagus and into the stomach. The MLMDT 
was inserted through the tube and then flushed down to the stomach with ±25mL of 
water. The animal was then allowed to recover which took approximately 15-25 
minutes.  
a) b) c) 
d) e) f) 
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26 Dosings
Group 1 Group 5Group 4Group 3Group 2
5 Pigs
Dosed with 
Theoplus®
CR 200
Dosed with 
Tilazem® CR 180
Dosed with THP-
loaded MLMDT’s
Dosed with DTZ-
loaded 
MLMDT’s
Dosed with 
placebo 
MLMDT’s
5mL samples collected from 
jugular vein at 2, 4, 6, 8, 10, 12, 
16, 20 and 24 hrs
5mL samples collected from jugular vein at 0.5, 1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 16, 20, 24 hrs
5 Pigs 5 Pigs 5 Pigs 1 Pig
 
Figure 5.4: Schematic diagram representing the different dosings. 
 
 
 
Figure 5.5: Digital image depicting the gastric tube used for administering the 
MLMDT’s. 
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5.3.4.4 Collection of blood samples 
Prior to obtaining the blood, both ports were flushed with 5mL heparinized saline. 5mL 
of blood was collected at 2, 4, 6, 8, 10, 12, 16, 20 and 24 hours from pigs dosed with 
conventional formulations (group one and two). Samples collected from group 3, 4 and 
5 were obtained at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20 and 24 hours. Blood 
samples were immediately transferred into heparinized vacutainers (BD Vacutainer®, 
New Jersey, USA) and centrifuged (Nison Instrument Limited, Shanghai, China) at 10 
0000rpm for 15 minutes. The clear plasma supernatant was pipetted using an 
adjustable volume micropipette (Boeco GmbH, Hamburg, Germany) and stored at 
−70°C until further analysis.  
 
5.3.5 Preparation of standards  
Primary stock solutions of THP and DTZ were separately prepared by adding Milli-Q 
(Millipore®) ultra-pure water to yield a concentration of 0.1mg/mL. The internal standard 
MP was prepared at a concentration of 5000ng/mL. The stock solutions were stored in 
polypropylene tubes with screw caps and stored in a refrigerator at 5°C. Working 
standard solutions of THP and DTZ were prepared separately by diluting the primary 
solution of each drug with Milli-Q (Millipore®) ultra-pure water to yield solutions with a 
final concentration range of 20-10 000ng/mL. The internal standard MP was prepared 
at a concentration of 5000ng/mL. Milli-Q (Millipore®) ultra-pure water and was added to 
all samples prepared for ULPC analysis. All solutions were filtered with a 0.22µm pore 
size Cameo Acetate membrane filter (Millipore Co., Massachusetts, USA). 
 
5.3.6 Plasma extraction procedure 
A simple yet effective liquid-liquid plasma extraction procedure was developed and 
applied to both DTZ and THP blood samples. Aliquots (600µL) of sample were 
transferred into polypropylene tubes followed by the addition of 1mL of acetonitrile in 
order to precipitate the plasma proteins. The samples were subsequently vortexed for 
1 minute and then centrifuged at 3000rpm (Nison Instrument Limited, Shanghai, China) 
for 20 minutes. Thereafter, 1mL of the supernatant was removed and filtered through 
0.22µm Cameo Acetate membrane filters. The filtrate and the internal standard were 
then combined and transferred into vials for analysis.  
 
5.3.7 Calibration curves and limits of quantification analysis 
Calibration curves were developed by spiking blank plasma with MP and various 
concentrations of either DTZ or THP. The spiked plasma samples were subjected to 
the extraction method described above. The ratio of the area under the (AUC) (of the 
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chromatogram) to drug/internal standard was profiled against the corresponding drug 
concentrations expressed in ng/mL. Linearity equations and correlation coefficients (rc) 
were obtained by means of the least square method. The limit of quantification (LOQ) 
is defined as the concentration which produces chromatographic peaks with heights at 
least 3 times that of the baseline noise. This concentration was determined for THP as 
well as DTZ.  
 
5.3.8 Chromatographic conditions for the analysis of blood samples 
A Waters® Acquity Ultra Performance Liquid Chromatographic (UPLC) system (Waters 
Corp., Massachusetts, USA) equipped with a photodiode array (PDA) detector was 
used to analyze the blood samples. Separation was achieved on an Acquity UPLC 
BEH RP 18 column (100mm x 2.1mm i.d., 1.7µm particle size) maintained at 25°C. 
The binary mobile phases and priming solvents are listed in Table 5.1. An injection 
volume of 2.5µL was injected in the mobile phase at a flow rate of 0.500mL/min. A total 
run time of 1.5 minutes was required at a wavelength of 238nm for DTZ and 280nm in 
the case of THP.  
 
Table 5.1: Mobile phases and priming solvent used for the determination of THP and 
DTZ in plasma samples. 
Solvent/Mobile Phase Composition 
Strong wash Acetonitrile (90% v/v) and water (10% v/v). 
Weak wash Acetonitrile (10% v/v) and water (90% v/v). 
Mobile Phase A (55%) Water 
Mobile Phase B (45%) Acetonitrile 
 
5.3.9 Extraction yield, precision and accuracy of the method 
Three duplicate plasma samples (both for THP and DTZ) at 3 different concentrations 
(20ng/mL, 1000ng/mL and 10 000ng/mL) were prepared and subjected to the 
extraction procedure mentioned above and injected into the machine. The percentage 
extraction yield was calculated by comparing the peak areas obtained from extracted 
analytes to those obtained from standard solutions at the same concentration. 
 
Intraday accuracy was determined by multiple injections (N=3) during a 24-hour period 
whereas the inter-day accuracy and precision of the method were determined by 
assaying multiple injections of the above concentrations over 3 consecutive days (N=3) 
and calculating the percentage deviation from the nominal concentration. 
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5.4 Results and Discussion 
 
5.4.1 In vitro drug release studies from MLMDT and comparator device 
In vitro drug release studies were conducted to determine the rate of drug release from 
optimized drug-loaded MLMDT’s and from popular existing THP (Theoplus® CR 200) 
and DTZ (Tilazem® CR 180) formulations. Theoplus® presents itself as a tablet 
whereas Tilazem® is a capsule loaded with controlled release beads. Upon exposure to 
the dissolution media swelling of the Theoplus® tablet was observed while exposure of 
the Tilazem® to dissolution media resulted in disintegration of the outer gelatin capsule 
and exposure of the inner controlled release beads. After the 24 hour study, Theoplus® 
had completely disintegrated, while the Tilazem® controlled release beads remained 
intact. A comparison of the rate of drug release between the drug-loaded MLMDT and 
the comparator products for both THP and DTZ are outlined in Figure 5.6. Observation 
of Figure 5.6a indicates a burst of drug release from the comparator product followed 
subsequently by controlled release. During this burst phase close to 40 % of drug is 
released within the first two hours. Drug release peaks at 8 hours indicating that the 
patient requires more than one dose in a day to maintain an adequate therapeutic 
response. The THP-loaded MLMDT exhibits the desired release profile and provides a 
lag phase and first pulse of drug release. This first pulse continued for duration of 3 
hours followed by a ―switch-off‖ phase of approximately 6 hours. Thereafter, a second 
pulse of controlled drug release for the remainder of the 24 hours was observed. This 
unique approach to drug delivery results in diminished exposure of the patient to the 
drug and eradicates the need for multiple dosing which fundamentally decreases side-
effects. Drug release from the DTZ conventional produces a similar trend (Figure 5.6b). 
Tilazem® presents with controlled release for the first 12 hours. Thereafter, a 5% 
increase in drug release between T12 and T24 is observed. This signifies that the patient 
may require more than one dose within a 24-hour period. The DTZ-loaded MLMDT 
displayed the desired release profile with a lag phase and an initial pulse of drug 
release continuing for approximately 3 hours. This was followed by a ―switch-off‖ phase 
of 8 hours and subsequently the a second pulse of drug release. 
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Figure 5.6: Drug release profiles depicting the comparison between a) THP-loaded 
MLMDT’s and the comparator product Theoplus® and b) DTZ-loaded MLMDT’s and 
Tilazem® (N=3, SD<0.071 in all cases). 
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5.4.2 In vivo animal studies 
 
5.3.2.1 Extraction of THP and DTZ from blood samples 
An uncomplicated, rapid method for extracting both THP and DTZ from blood samples 
has been developed. The straightforward process proved to remove plasma 
constituent interference from the plasma samples. The assay did not demonstrate any 
interference from plasma components. 
 
5.4.2.2 Chromatograms for THP and DTZ plasma 
A typical chromatogram portraying the retention of THP and DTZ combined with the 
internal standard MP is represented in Figure 5.7 and Figure 5.8. THP exhibits a 
retention time of 0.424±0.02 minutes while DTZ elutes at 0.435±0.02 minutes. A 
positive control assay to determine the efficacy of the extraction method was 
performed by analyzing blank plasma spiked with MP (Figure 5.9). The chromatogram 
demonstrated no interference peaks at the retention times of both THP and DTZ, 
indicating that the extraction method was effective.  
 
 
Figure 5.7: Chromatograms depicting the retention times of THP and MP in plasma.  
  
THP MP 
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Figure 5.8: Chromatograms depicting the retention times of DTZ and MP in plasma. 
 
 
Figure 5.9: Chromatogram obtained from drug-free plasma spiked with MP 
demonstrating no interference peaks.  
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5.4.2.3 Calibration curves and lower limit of quantification 
Figure 5.10 and Figure 5.11 represents the calibration curve for the quantitative 
determination of plasma THP and DTZ respectively. Concentrations of both drugs 
ranged from 20ng/mL -10 000ng/mL and displayed good linearity (R2=0.99). The lower 
limit of quantification was determined as 19.7ng/mL for THP and 20ng/mL for DTZ. 
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Figure 5.10: Calibration curve for THP in blank plasma 280nm (N=3, SD<0.031 in all 
cases). 
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Figure 5.11: Calibration curve for DTZ in blank plasma 238nm (N=3, SD<0.041 in all 
cases). 
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5.4.2.4 Method validation for analysis of THP and DTZ in plasma employing 
UPLC analysis 
Results from method validation assays for THP and DTZ are summarized in Table 5.2 
and Table 5.3 respectively. Results indicated that the implemented extraction and 
assay procedure displayed acceptable accuracy and precision. 
 
Table 5.2: Method validation data for THP. 
 
 
 
Table 5.3: Method validation data for DTZ. 
CV=Coefficient of Variation 
 
5.4.2.5 In vivo drug release analysis 
In vivo drug release profiles of the MLMDT’s and their conventional comparator 
products are portrayed in Figure 5.12 and 5.13. The plasma time-concentration profiles 
display immediate release from both conventional products. Plasma drug 
concentrations reach a maximum after 2 hours (Tmax = 2 hours). Thereafter, drug 
concentrations decline as the elimination process commences.  
 
Plasma time-concentration profiles from both THP-loaded and DTZ-loaded MLMDT’s 
display immediate drug release during the first hour. This is followed by a decrease in 
drug release after 2 hours. This initial burst of drug release corresponds to the first 
pulse of release emanating from D1 though no initial lag phase is observed. The 
decrease in drug concentration after 2 hours corresponds to the ―switch-off‖ phase 
separating the two pulses. The ―switch-off‖ phase is however, not as pronounced as 
demonstrated from in vitro data. Even though no drug is released into the blood during 
this ―switch-off‖ phase, drug is nonetheless present in the blood and undergoing 
elimination. As a result, a distinct, pronounced ―switch-off‖ phase is absent. Thereafter, 
Theoretical plasma THP 
concentration (ng//mL) 
Intra-day Inter-Day 
 Extraction 
yield (%) 
CV 
(%) 
Extraction 
yield (%) 
CV 
(%) 
20 95.03 0.024 95.42 0.025 
1000 97.58 0.020 97.14 0.029 
100 000 98.96 0.017 98.90 0.021 
Theoretical plasma DTZ 
concentration (ng/mL) 
Intra-day Inter-Day 
 Extraction 
yield (%) 
CV 
(%) 
Extraction 
yield (%) 
CV 
(%) 
20 98.57 0.016 98.61 0.022 
1000 98.85 0.020 98.70 0.024 
100 000 99.06 0.017 98.92 0.030 
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the second pulse is observed with the THP-loaded MLMDT reaching peak plasma 
concentration (Tmax) after 6 hours and DTZ-loaded formulations attaining a maximum 
concentration of 887.46ng/mL at Tmax = 5 hours. Both drug-loaded MLMDT’s displayed 
two phase release though the ―switch-off‖ phase was not as distinct compared to the in 
vitro data obtained. 
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Figure 5.12: Comparison between in vivo plasma concentration-time profiles for a) 
THP (optimized) and b) Theoplus® 200 (conventional) with P1 representing the first 
pulse of drug release and P2 representing the second pulse of drug release (N=5; 
SD<0.13 in both cases). 
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Figure 5.13: Comparison between in vivo plasma concentration-time profiles for: a) 
DTZ (optimized) and b) Tilazem 180 CR (conventional) with P1 representing the first 
pulse of drug release and P2 representing the second pulse of drug release  
(N=5; SD<0.14 in both cases). 
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5.5. Concluding Remarks 
 
The proposed novel MLMDT consists of two drug loaded disks enveloped by drug-free 
polymeric layers comprising PEC/AVC, HPMC, EC and HEC. THP and DTZ-loaded 
MLMDT’s were evaluated for drug release along with conventional systems namely 
Theoplus® CR 200 and Tilazem® CR 180. In vitro drug release results revealed two 
pulses of drug release from the MLMDT’s while the conventional systems provided 
sustained release for 8 and 12 hours from Theoplus® a and Tilazem® respectively. In 
addition, a method which served to improve blood sampling was developed through 
the use of chronic implanted jugular catheters. Furthermore, a simple yet efficient 
extraction and analysis method was developed for both drugs. In vivo plasma time-
concentration profiles illustrated a first pulse of drug release followed by a slight 
decrease in drug release after 2 hours and followed by controlled release. Two phase 
drug release in both THP and DTZ-loaded MLMDT’s was observed though the ―switch-
off‖ phase was not as prominent as data obtained from in vitro analysis. Both 
Theoplus® and Tilazem® conventional formulations display increasing plasma 
concentrations up to 2 hours followed by a steady decline in concentrations. As a 
result, the proposed MLMDT proved superior to the conventional as two pulse drug 
release was achieved.  
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CHAPTER SIX 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
6.1 Conclusion  
 
With the advancement of technology and a better understanding of disease conditions, 
the concept of chronotherapy still remains largely unexplored. Current 
chronotherapeutic formulations on the market are not able to time drug release with the 
body’s circadian rhythm leading to unwanted side-effects that may be avoided. As a 
result, a drug formulation needs to be efficacious, accessible and affordable. In the 
South African context, an affordable dosage form is welcomed as a large number of 
patients rely on government funded healthcare. 
 
To address the above challenges, the MLMDT proposed here, aims to decrease side-
effects and eliminate multiple dosing during a 24-hour period. This leads to a decrease 
in the cost of treatment and thus an increase in patient compliance. In addition, the use 
of low-cost FDA approved polymers and a cost-effective tablet making procedure 
results in an affordable dosage form. 
 
Preliminary in vitro testing allowed for the selection of appropriate polymers to be 
employed in the MLMDT formulation. Both hydrophobic and hydrophilic polymers were 
evaluated for drug release in order to obtain the desired release profile. Drug release 
data depicted a lag-phase followed by phasic release.  
 
Using Artificial Neural Network techniques optimized formulations were determined. 
Drug release data demonstrated an initial lag-phase followed by two pulses of drug 
release separated by a ―switch-off‖ phase. The formulations were subsequently 
evaluated for hardness, friability, swelling, erosion, uniformity in the tablet making 
process and incompatibilities. All tested parameters fell within the acceptable range. 
 
Drug release from the optimized drug-loaded MLMDT’s was then compared to drug 
release from conventional formulations currently on the market, namely Theoplus® CR 
(THP) and Tilazem® (DTZ). The in vitro drug release data obtained from the analysis of 
both conventional formulations demonstrated controlled release over a period 8 hours 
in the case of Theoplus® and 12 hours in the case of Tilazem®. Furthermore no pulse 
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release was observed. Analysis from the drug-loaded MLMDT’s illustrated two pulses 
of drug release with release continuing over the full 24-hour period proving the MLMDT 
to be superior to the respective conventional products.  
 
The optimized MLMDT and the conventional formulations were also subjected to in 
vivo animal studies using the Large White Pig as an animal model. A convenient 
method of drawing blood from the pigs was developed which required surgery to 
catheterize the left vein jugular. External injection points were sutured to the back of 
the pig. Blood was drawn via these ports at predetermined time intervals, centrifuged 
and then stored until use. Analyses of the plasma samples were conducted using a 
developed simple and effective method of plasma extraction. The extracted plasma 
was subjected to analysis using UPLC to determine drug concentrations.  
 
Plasma time-concentration profiles for both conventional formulations displayed 
immediate drug release with maximum drug concentrations reached in 2 hours 
followed by an elimination phase. The MLMDT’s demonstrated immediate release 
during the first 2 hours followed by a ―switch-off‖ phase. Thereafter, a second phase of 
drug release was observed. This phase demonstrated controlled release over the 
remaining 24-hours. As a result, the MLMDT proved superior to the conventional in the 
treatment of chronotherapeutic disorders by affording phasic drug delivery.  
 
6.2 Recommendations 
While this drug delivery system has been developed for use in the treatment of 
chronotherapeutic disorders, it is not exclusive to these diseases as the MLMDT may 
be loaded with drugs of varying solubilities. The system also allows the versatility of 
combining two drugs in the same dosage form to treat two disorders. The system may 
also be used to combine two drugs that are pharmaceutically incompatible in one 
dosage form or if drug is to be delivered to more than one site along the GIT.  
 
The approach used in this study may also be employed to determine the effect of a 
change in the size or shape of the disk on drug release. The addition of a third and 
even fourth disk may also be explored. The additional disks may contain drug or 
crosslinking agents to further regulate drug release. 
 
Animal studies in the pig model have shown some promise. As a result, testing should 
now be performed in the human model.  
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Purpose 
 
It has been established that certain diseases are known to follow a circadian rhythm. 
Most conventional therapies include once-daily preparations that provide sustained 
zero-order release. However, they are not designed to complement the body’s 
circadian rhythm. This gives rise to the concept of chronotherapy which involves 
synchronizing drug application in a manner that matches circadian rhythm to achieve 
optimal therapeutic success. The aim of this study was to evaluate the drug release 
behavior from a polyconcentric designed disk-loaded matrix for use in treating 
chronotherapeutic diseases. 
 
Methods 
 
Preparation of the device: Drug-loaded disks were prepared using model drug 
theophylline. Polymers that were used included various permutations of cellulose-
based and polyester-type polymers. Disks were incorporated into tablet matrices by 
direct compression in alternating layers of either cellulose or polyester-type polymers. 
Drug release characteristics were studied using a rotating paddle method dissolution 
apparatus (USP 25 Apparatus 2) with a stirring speed of 50 rpm at 37 ±0.5º in 900 mL 
phosphate buffer (pH 6.8) over 24 hours.  
  
Results 
 
Drug release ranged from 9-15% during the 24 hour period when swellable cellulose-
based polymers were employed. The reduced release rate occurred as a result of the 
large diffusion interface created by the hydrated cellulose polymeric layer. However, 
this did contribute to a lag time which varied between 7-10 hours. The length of the lag 
time was strongly dependent on the polymer used in the outer layer, for example 
hydroxypropyl methylcellulose (HPMC) in an outer layer demonstrated a longer lag 
time as compared to polyethylene oxide (PEO). Further research is currently underway 
in order to increase the drug release rate over a 24 hour period in an attempt to attain 
a suitable once-daily drug delivery system for chronotherapeutic disorders. 
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Purpose 
Although zero order drug release remains a favorable form of drug release, increasing interest 
has been placed on timed pulsatile drug release, where drug is released at predetermined 
intervals after a lag phase. This form of drug release is advantages for chronotherapeutic 
disorders as well as to treat diseases of the colon. The aim of this work is to evaluate drug 
release from discoid matrices using both a water soluble and insoluble model drug.  
 
Methods 
Preparation of the device: Drug-loaded disks were prepared using model drug theophylline 
and diphenhydramine. Various polymers were employed and included HPMC, EC and pectin. 
Drug disks were incorporated into tablet matrices by direct compression between alternating 
layers of the various polymers. 
Drug Release Studies: Drug release characteristics were studied using a rotating paddle 
method dissolution apparatus (USP 25 Apparatus 2) with a stirring speed of 50 rpm at 37 ±0.5º 
in 900 mL phosphate buffer (pH 6.8) over 24 hours. 
Textural Analysis: Textural analysis was used to determine the swelling characteristics of the 
hydrated formulations. Tablets were exposed to the same conditions above and at 
predetermined time interval (2, 6, 8, and 10 hours) tablets were removed and lightly patted with 
tissue paper to remove excess water. Textural profiling was performed TA.X2plus texture 
analyzer (Stable Micro Systems, Surrey, England) fitted with a flat-tipped steel probe (2mm 
diameter). 
Erosion Studies: Tablets were exposed to conditions above and at predetermine time intervals 
(2, 6, 8 and 10 hours) tablets were removed and placed in an oven until a constant weight was 
achieved. The samples were then gravimetrically analyzed.  
  
Results  
Drug release from the theophylline matrices displayed an initial lag phase of three hours during 
which no drug release occurred. Thereafter the first phase of drug release occurred up to six 
hours, after which a second lag phase was seen. A second phase of drug release subsequently 
resumed after 12 hours with 73% drug release occurring after 24 hours. The lag phase seen 
between the first and second phase of drug release lasted for approximately six hours. Drug 
release from diphenhydramine matrices differed somewhat, with no lag phase seen initially. 
Instead, a burst effect is seen with approximately 28% of drug release occurring within the first 
hour. This is followed by a period between one and five hours were no drug release occurs after 
which complete drug release is achieved in 12 hours. The burst effect seen with the 
diphenhydramine formulation is attributable to its high water solubility (≥100mg/ml) as 
compared to theophylline formulation (solubility 1-5mg/ml) where a lag phase is seen initially 
with drug being released at a slower rate over 24 hours. Textural analysis results showed DPH 
formulations reaching a diameter of 8.105mm at T10 whereas theophylline formulations only 
reached a diameter of 7.844mm. In addition, after the first two hours the DPH formulation had a 
greater diameter than the theophylline formulation. Erosion studies show that the rate of erosion 
in the Theophylline formulations (46.75%) is higher than in DPH formulations (42.65%) after T10. 
This is comparable to the swelling studies where theophylline formulations have a smaller 
diameter, suggesting that the theophylline formulations erode to a greater degree than DPH 
formulations.  
Conclusion 
Both diphenhydramine and theophylline formulations show pulsatile release. Diphenhydramine 
formulations, however, do not display an initial lag phase.   
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Purpose: 
To evaluate the drug release kinetics, erosion and swelling dynamics from a directly 
compressed layered disk matrix. 
 
Methods: 
Matrices comprising two drug loaded disks where compressed between three 
polymeric layers of HPMC, Pectin and a HPMC/Pectin blend. Diphenhydramine HCL 
(solubility ~1g/mL) was used as a model drug and ethylcellulose and HPMC were 
employed for the drug discoid matrices. Drug release studies were performed using 
USP dissolution apparatus II comprising 900mls PBS (pH 6.8; ±37°C) at 50rpm for 12 
hours. Swelling and erosion studies were conducted under similar conditions.  
 
Results: 
Drug release displayed biphasic drug release with an initial burst phase followed by 
controlled release. Matrices with pectin as a top layer, displayed a lag phase of 4 hours 
after the initial burst. Erosion followed a linear increase where matrices with pectin 
displayed the highest erosion (42% SD±0.15). Swelling studies showed a range of 
between 55-155% at t1 hour. Matrices with pectin displayed an increased in swelling up 
to 6 hours, after which swelling decreased and then increased. This is comparable to 
the erosion of the pectin top layer.  
 
Conclusion: 
Formulations displayed biphasic release with a drug-free period between the two 
phases of drug release thus providing pulsatile release. 
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Purpose: 
The purpose of this research is to develop a multi-layered multi-disc tablet for use in a 
chronotherapeutic disorder such as hypertension, asthma, cardiac disease and 
stomach ulcers. This device should produce biphasic drug release achieved through 
the use of two drug loaded disks, with the crown disk providing the first phase of drug 
release and the base disk providing the second phase of drug release.  
 
Methods: 
Preparation of the device: To produce a base disk, various ratios of the polymers 
HEC and EC were granulated with model drug theophylline using an aqueous 
dispersion of EC as granulating fluid. The granules were then compressed using a 
Beckman Hydraulic Press into drug disks. The crown disk comprised pure theophylline, 
with lactose used as a bulking agent. The disks were suspended between layers of 
HPMC and Pectin using a flat faced punch and die set. 
Drug release studies: Drug release studies were performed using USP dissolution 
apparatus II comprising 900mls PBS (pH 6.8; ±37°C). Matrices were subjected to 
dissolution for 24 hours at 50rpm. 
FTIR: FTIR analyses was undertaken to assess any possible structural variations in 
the polymeric backbone, as a result of any interactions of the drugs, excipients, or 
polymers themselves, in the formulation. Analyses was carried out on the native 
polymers, the granulation blend and the compressed formulations.  
DSC: Differential scanning calorimetry was undertaken to analyse changes, such as glass 
transition temperature of the polymer, melting point and any interaction between the polymers, 
excipients or drug during formulation. Samples were run from 0-300°C at a heating rate of 10ºC 
per minute. Analyses were carried out on the native polymers, the granulation blend and the 
compressed formulations. 
 
Results: 
Drug release for all formulations displayed biphasic release with an initial lag phase of 
approximately 3 hours, followed by a burst of drug release between t=3 and t=5 hours. 
Thereafter drug release sustained release is observed for the remainder of the 24 hours with 
drug release ranging from 70-90%. Formulations with a 2:1 ratio of EC to HEC however, 
display a drug free period of approximately 5 hours after the initial burst. As a result, this 
formulation is able to provide two phases of drug release and may have applications in 
chronotherapeutic drug delivery. FTIR analyses show no significant changes in both the 
polymeric and drug structure as a result of granulation and compression. This is further 
motivated by DSC analyses which show no change in the Tg and melting points of the various 
polymer and drug.   
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Purpose: 
To investigate the effect of different polymer blends on drug release from a directly 
compressed layered disk system and to determine if any interactions are present 
between the polymers and the drug.   
 
Methods: 
The polymers HEC, HPMC and EC were granulated with model drug theophylline 
using an aqueous dispersion of EC as granulating fluid. The granules were then 
compressed using a Beckman Hydraulic Press into drug disks. The disks were 
suspended between alternating layers of HPMC using a flat faced punch and die set. 
Drug release studies were performed using USP dissolution apparatus II comprising 
900mls PBS (pH 6.8; ±37°C). Matrices were subjected to dissolution for 24 hours at 
50rpm. Fourier transform infrared (FTIR) spectroscopy was utilized to determine any 
structural variations in the polymer backbone as a result of any interactions between 
the drug and polymers. A textural analysis was used to determine the Indentation 
hardness and thus the Brinell Hardness Number (BHN).  
Results:  
Drug release in all formulations displayed biphasic drug release with an initial lag 
phase of between 6-8 hours. Drug release from formulations comprising HEC 
displayed the highest drug release (71% SD ±0.11) followed by HPMC containing 
formulations (62% SD±0.13) and lastly EC formulations with incomplete drug release 
(34% SD± 0.12). This is due to the hydrophobic nature of EC. FTIR analyses displayed 
no change in the structure of both the polymer and the drug suggesting that no 
interactions are present. FTIR analyses also showed no structural variation between 
compressed and uncompressed forms of the system. Textural analyses data 
performed on drug disks displayed BHN values ranging from 1.8-2.2 N/mm2 with EC 
formulations displaying the highest value.   
 
 
Conclusion: 
Formulations displayed biphasic release with a lag phase thus demonstrating desirable 
release kinetics for the treatment of chronotherapeutic formulations.  
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Introduction: 
Research suggests that chronotherapeutic disorders such as asthma and hypertension 
would benefit from timed-pulsatile drug release. Therefore, drug should be released at 
times when it is most needed to minimize adverse effects. 
 
Purpose: 
To develop a novel multi-layered disc tablet with a crown disc and a base disc that 
produces two-phase release. 
 
Methods: 
The base disc was produced by granulating theophylline with HEC and EC using an 
EC aqueous dispersion as a granulating fluid. The crown disc comprised theophylline 
with lactose as a bulking agent. These discs were suspended between layers of Pectin 
and HPMC. Drug release studies were performed using a USP apparatus II (pH 6.8; 
±37°C) at 50rpm. FTIR and DSC analyses were performed to assess any structural 
changes as a result of interactions between the polymer and drug. 
  
Results: 
Drug release studies show two phases of drug release, with an initial burst occurring 
between T=2hours and T=4hours, a drug free period of approximately 5 hours and 
thereafter controlled release over the remaining 24 hours. FTIR analyses and DSC 
analyses showed no changes in the structure, Tg and melting points of the drug and 
polymers. 
  
Conclusion: 
A novel layered chronotherapeutic system has been developed.   
 
Funding has been provided by BioPad. 
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Introduction: 
Chronopharmaceutics is a branch of pharmaceutics that is devoted to the design and 
evaluation of drug delivery systems that release a bioactive agent at a rhythm that 
ideally matches the biological requirements of a given disease therapy (Youan, 2004). 
By using the concept of chronotherapy, it would be ideal to time drug application within 
the 24 hours of a day such that drug is released when it is required. Furthermore, by 
timing drug application, the pharmacokinetics and/or drugs side effects may be 
modified (Lemmer, 1996; Mastiholimath, 2007).  
 
The present study aims to develop a multi-layered multi-disc tablet (MLMDT) with a 
two-phase release and lag phase for use in chronotherapeutic disorders. Conventional 
controlled release preparations release the same amount of drug throughout the day. 
Accordingly, drug is released even at times when it may not necessarily be required, 
exposing the patient to unnecessary quantities of drug. This device should produce a 
two-phase release which is achieved through the use of two drug loaded disks, with 
the crown disk providing the first phase of drug release and the base disk providing the 
second phase of drug release.  
 
Methods: 
Preparation of the device: To produce a base disk, various ratios of the polymers 
HEC and EC were granulated with model drug theophylline using an aqueous 
dispersion of EC as granulating fluid. The granules were then compressed using a 
Beckman Hydraulic Press into drug disks. The crown disk comprised pure theophylline, 
with lactose used as a bulking agent. The disks were suspended between layers of 
HPMC and Pectin using a flat faced punch and die set. 
Drug release studies: Drug release studies were performed using USP dissolution 
apparatus II comprising 900mls PBS (pH 6.8; ±37°C). Matrices were subjected to 
dissolution for 24 hours at 50rpm. Samples were removed at regular intervals and 
tested using a UV spectrophotometer at a wavelength of 280nm.  
FTIR: FTIR analyses was undertaken to assess any possible structural variations in 
the polymeric backbone, as a result of any interactions of the drugs, excipients, or 
polymers themselves, in the formulation. Analyses was carried out on the native 
polymers, the granulation blend and the compressed formulations.  
DSC: Differential scanning calorimetry was undertaken to analyse changes, such as glass 
transition temperature of the polymer, melting point and any interaction between the polymers, 
excipients or drug during formulation. Samples were tested from 0-300°C at a heating rate of 
10ºC per minute. Analyses were carried out on the native polymers, the granulation blend and 
the compressed formulations. 
In vivo studies: In vivo animal studies were carried out using healthy female pigs weighing 
between 35 and 45 kg. The pigs were dosed with a conventional theophylline tablet 
(Theoplus
®
), a placebo and the novel system via an intra-gastric tube. Blood samples were 
collected over a period of 24 hours and analysed via UPLC.  
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Results: 
In vitro drug release studies show that formulations with a 2:1 ratio of EC to HEC show optimal 
drug release. Drug is released in a phasic manner after a lag phase of approximately 2 hours. 
The first phase of drug release occurs between t=2 and t=4 hours followed by a drug free period 
of approximately 5 hours during which no drug release is observed. Thereafter drug release 
resumes and is maintained over the remaining 24 hours. In vivo animal studies support this data 
with placebo studies showing no adverse effects on the pigs. In addition, when compared to the 
conventional theophylline formulation (Theoplus
®
), the novel MLMDT is able to produce 
phasic drug release proving that the MLMDT is superior to the conventional formulation in 
terms of producing a two phase release. FTIR analyses FTIR analyses show no significant 
changes in both the polymeric and drug structure as a result of granulation and compression. 
This is further motivated by DSC analyses which show no change in the glass transition 
temperature and melting points of the various polymer and drug.  
 
Conclusions: 
A novel multi-layered multi-disc tablet capable of producing two-phase release to be used in the 
treatment of chronotherapeutic disorders has been developed.  
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